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ABSTRACT 
Biodegradable and biocompatible polymeric nanoparticles such as poly (lactide-co-glycolide) 
(PLGA) nanoparticles have been extensively studied as drug delivery systems for a variety of 
pharmaceutical agents. Nanoparticle surface properties are primarily determined by the 
emulsifiers used in the synthesis process, which have a significant impact on nanoparticle 
physico-chemical and biological properties. Anionic amino acid – based molecular micelles were 
used in the emulsification process to prepare monodisperse, small (below 100 nm) PLGA 
nanoparticles with a well defined spherical shape. Such molecular micelle – modified 
nanoparticles were used as drug carriers for delivery of antioxidants. Thymoquinone is a natural 
antioxidant, and an emerging anticancer drug found in Nigella sativa black seed oil. 
Thymoquinone – loaded nanoparticles demonstrated improved properties when compared with 
the free drug, suggesting that such nanoparticle systems are promising candidates for antioxidant 
delivery and tumor growth inhibition. Furthermore, polymeric nanoparticles were used as 
sensors for detection of hydroxyl radicals. Ratiometric fluorescent molecular micelle – modified 
PLGA nanoparticles were designed using a reporting dye (coumarin – functionalized molecular 
micelle) present on their surface as well as a reference dye (neutral red) encapsulated into the 
polymeric matrix. The nanoparticles were able to detect hydroxyl radicals in a time and 
concentration dependent manner, and presented high selectivity for hydroxyl radicals as 
compared with other reactive oxygen species. In addition, the ratiometric fluorescent 
nanosensors were able to detect hydroxyl radicals in viable cells exposed to oxidative stress, 
allowing their potential use in the study of other living systems. 
 1 
CHAPTER 1 
INTRODUCTION 
1.1 Nanotechnology and Drug Delivery Systems 
If we were to build a scale of things, we would start by thinking about how big a planet is 
or how high we have to climb to the peak of a mountain. In contrast, we observe small objects 
around us such as the head of a pin (2 mm) or the width of a hair (50-150 µm). However, there is 
a smaller scale that we cannot see, the nanometer scale. For example, a double DNA strand is 
only a few nanometers in diameter. In addition, nanometer size materials offer unique properties. 
For example, quantum dots have size-dependent spectral properties, emitting light from blue to 
red and into the near-infrared. In the medical field, drug-loaded nanoparticles can target specific 
cells or can migrate through the blood brain barrier while the drug itself cannot.1, 2 Therefore, 
science and technology are focused nowadays towards the nanometer scale, specifically to take 
advantage of such nanoscale properties. 
The fabrication, characterization, and application of structures and devices having tunable 
properties determined by their nanometer size (≤100 nm) represent the discipline of 
nanotechnology.3, 4 Nanotechnology is constructed on a strong foundation of cumulative efforts 
of chemists, biologists, physicists and engineers. Their goals include the discovery and the 
development of new and innovative technologies, assessment of social and health risk factors as 
well as sustainability for future generations.5-7 Since the lecture of Richard Feynman entitled 
“There is plenty of room at the bottom” at CalTech in 1959, the development of nanotechnology 
has increased dramatically.8-10 The transition from the macroscopic materials and devices to the 
nanoworld has been observed in many areas including material science, energy, agriculture, 
communications, environment, health care, and aerospace. Recently, a research group from the 
University of Arizona has developed an internet based database, called “nano mapper” 
 2 
(http://www.nanomapper.eller.arizona.edu/), where one can search the number of patents related 
to nanotechnology published worldwide.11 For example, using “nano” as keyword, the search 
results indicated that the United States Patent and Trademark Office has issued more than 3000 
nano-patents. A significant number of patents was also released by the European and Japanese 
Patent Offices.   
As a result of continuous growth in this field, more than 35 countries have initiated 
governmental funding programs related to nanotechnology. For example, the Japanese 
government allocated more than $800 million to nanotechnology projects in 2003, followed 
closely by the United States with approximately $774 million, representing six times more than 
in 1997.12 In a report released by the National Nanotechnology Initiative (NNI), the central 
nanotechnology authority in the United States, the proposed NNI budget for 2010 is $1.64 
billion. Such financial support was designated to contribute not only to the development of 
nanotechnology, but also to its impact on Environment, Health, and Safety (EHS).13 Similarly, 
the European Commission Framework Programme proposed a total budget of 50 billion Euro for 
2007-2013 that focuses on nanoscience, the production of new nanomaterials, and the 
development of nanotechnologies. In addition, multinational programs such as STAGE, 
NANOROADMAP, and FRAMINGNANO, have been developed for public engagement, 
education and communication throughout the European countries.14 
One important area of nanotechnology is nanomedicine. It includes the investigation and 
the development of nanoscale surgery, tissue engineering, and drug delivery systems that lead to 
improved diagnosis and therapy.1, 15 The efforts of the pharmaceutical industry have been 
directed towards new bioactive compounds that interact with biological molecules depending on 
local, sustained, or stimuli-triggered delivery.16 Several important aspects of drug delivery 
systems are depicted in Figure 1.1. Active pharmaceuticals can be classified into four classes. 
 3 
Class I includes compounds that have the highest permeability through cell membrane and the 
highest water solubility. In contrast, class IV drugs have the lowest bioavailability, and hardly 
reach the market. However, drugs from classes II and III possessing low bioavailability, 
determined by either low solubility or low permeability, are candidates for drug delivery 
systems.17  
 
 
Figure 1.1 Principal characteristics of drug delivery systems. 
 
In addition, biocompatible materials should be used as carriers in order to avoid 
inflammatory response and clearance from the body before reaching their site. Therefore, on one 
side, drug properties such as bioavailability, biocompatibility, and stability are relevant for the 
design of drug delivery systems that improve such properties.  On the other side, questions such 
as how and where the drug is administered need to be addressed as well. Whether the drug 
delivery system is ingested or administered intravenously, targeted delivery becomes possible by 
functionalized surfaces that trigger direct responses from specific cells or intracellular 
components.18-20  
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Numerous pharmaceutical compounds can be delivered via various routes by use of 
nanoparticles. Oral drug administration is preferred based on patient convenience. However, 
many drugs are not resistant to the acidic environment present in the gastrointestinal tract. 
Therefore, intravenous administration is commonly used. In such cases, colloidal aqueous 
suspensions should contain submicron nanoparticles in order to avoid deposition and clogging of 
blood vessels. 
Another important aspect of drug delivery systems is the release mechanism. For 
example, the drug can be delivered at a steady concentration over a period of time, or can present 
a burst release for a short period of time followed by constant release. In other cases, the drug 
can be released under the effect of external stimuli such as pH, temperature, and ionic strength. 
In addition, controlled drug delivery systems provide prolonged delivery at an optimum drug 
level as compared with a fluctuating free drug administration.  Furthermore, drug delivery 
systems can be designed to target specific cells and tissues, and to provide drug protection 
against degradation. In addition, such systems lead to improved general comfort of the patient 
determined by reduced number of doses, and minimized undesirable side effects. 21-23 
1.2 Polymeric Nanoparticles as Drug Delivery Systems 
 There is a multitude of nanomaterials that can reach pharmaceutical performance of drug 
delivery systems. They include polymeric nanoparticles, solid lipid nanoparticles, cyclodextrins, 
liposomes, quantum dots, carbon nanotubes, and gold nanoparticles.20, 24, 25 However, 
biodegradable materials are preferred specifically due to their biodegradability and compatibility 
with the human body. For example, poly (lactic acid), poly (glycolic acid), and their copolymer, 
poly (lactide-co-glycolide) (PLGA), are FDA approved biodegradable polymers previously used 
for scaffolds and tissue engineering. Nanoparticles prepared from such polymers would likely 
have less toxic effects than other nanomaterials used for preparation of drug carriers. In addition, 
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several other attractive properties such as degradation of the monomers through normal 
metabolic paths, versatility of preparation methods, and the variety of molecules to be delivered 
make PLGA nanoparticles the state of the art in drug delivery.26, 27  
The market of polymeric nanoparticles used as drug delivery systems has expanded 
considerably in the last years. The first FDA approved drug delivery system was developed by 
TAP Pharmaceutical Products for prostate cancer treatment with leuprolide acetate using 
injectable PLGA microparticle system. Other drug delivery systems such as PLGA nanoparticles 
for human growth hormone delivery and albumin-stabilized nanoparticles for paclitaxel delivery 
are available on the market or in clinical trials.27-29 
There are two types of polymeric nanoparticles: nanosheres and nanocapsules, as shown 
in Figure 1.2. A hydrophobic active agent can be entrapped in the polymeric matrix of 
nanospheres while a hydrophilic drug can be encapsulated into the nanocapsule core. In both 
cases, the drug can be adsorbed or chemically bound to the nanoparticle surface as well.30-32 
Using this variety of approaches, polymeric nanoparticles have been extensively investigated as 
delivery systems for anticancer drugs,33, 34 gene therapy,35 and protein delivery.36 
 
 
Figure 1.2 Nanospheres and nanocapsules as drug delivery systems.  
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1.2.1 Methods of Preparation 
Polymeric nanoparticles can be prepared by a multitude of methods. 18, 37-39  Depending on the 
type of drug, preparation methods such as emulsion – evaporation and emulsion – diffusion can 
be specifically adopted for nanospheres incorporating hydrophobic drugs.40-45 In addition, a 
double water-in-oil-in-water  emulsion has been used for the encapsulation of water soluble 
active agents such as proteins and DNA.46, 47 
Emulsification solvent evaporation is one of the most commonly used methods for the 
preparation of polymeric nanoparticles delivering hydrophobic drugs. A simple scheme of 
emulsification solvent evaporation method is illustrated in Figure 1.3. In this method, the 
polymer and the drug are dissolved in a water-immiscible organic solvent such as ethyl acetate, 
dichloromethane and chloroform. The organic phase is finely dispersed in a large aqueous phase 
containing an emulsifier, using high shear forces such as homogenization and sonication. 
 
 
Figure 1.3 Basic principles of emulsification solvent evaporation method. 
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The organic solvent is then evaporated, leading to solidification of polymeric spheres. 
Parameters such as drug – polymer compatibility, the organic to aqueous phase ratio, evaporation 
speed as well as the intensity and time of homogenization play an important role in the synthesis 
of nanoparticles. For example, highly hydrophobic drugs can be encapsulated into polymers with 
a high content of lactide. In addition, a small organic to aqueous phase ratio often leads to small 
size nanoparticles. Removal of excess emulsifier and un-entrapped drug are critical aspects of 
nanoparticle synthesis as well. Therefore, purification by various methods such as dialysis and 
centrifugation follows the nanoparticle synthesis. For long term storage, nanoparticles are 
typically dried to powder form and re-suspended in aqueous media before use.  
Other methods such as nanoprecipitation and diffusion can also be used for nanosphere 
preparation. The basic principle of these methods is similar to the one presented in Figure 1.3. 
However, they involve the use of a water miscible solvent and slow solvent evaporation in a 
larger aqueous phase. Particle sizes above 100 nm and poor drug entrapment limit such methods 
for their use in the preparation of polymeric nanoparticles. 
1.2.2 Characterization of Polymeric Nanoparticles 
 The benefits of drug delivery systems based on polymeric nanoparticles are mainly 
determined by their physico-chemical properties such as particle size, zeta potential, shape and 
surface appearance as well as drug content and release. There are numerous methods for 
characterization of nanoparticles, as shown in Figure 1.4. For example, important aspects such as 
particle size, polydispersity, surface charge, and morphology are investigated by use of dynamic 
light scattering and imaging techniques. In contrast, separation techniques and spectroscopy can 
be used for the determination of drug content. In addition, toxicity and in vitro performance of 
nanoparticle-based drug delivery systems involve cell culture analyses. Several methods used in 
this dissertation are described below. 
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Figure 1.4 Methods for nanoparticle characterization. DLS – Dynamic Light Scattering; 
TEM – Transmission Electron Microscopy; HPLC – High Performance Liquid 
Chromatography. 
 
1.2.2.1 Size and Polydispersity 
Particle size and size distribution (polydispersity) are important characteristics of 
polymeric nanoparticles. Small nanoparticles of 100 nm are suitable for oral and parenteral 
administration and have better cellular uptake as compared to microparticles.18, 35 Particle size is 
typically determined by use of dynamic light scattering, also known as photon correlation 
spectroscopy. 
Dynamic light scattering (DLS) is based on variations in time of the intensity of scattered 
light from a monodisperse colloidal nanoparticle suspension. Such variations are the result of the 
nanoparticle translational and rotational Brownian motion in solution. The intensity of scattered 
photons is measured in channels that are further correlated. The correlation function, g (1) (τ), is 
given by equation 1.1: 
( ))(exp)( 2
)1(
ττ Dqg −=                     1.1 
where τ is the decay time; q = 4pin/λ0sinΘ/2 is a scattering factor dependent on refractive index  
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n, incident light wavelength, λ0, scattering angle ,Θ, and diffusion coefficient, D.
48 
The hydrodynamic radius of a nanoparticle, Rh (m), is determined based on the Stokes – 
Einstein formula (equation 1.2): 
D
kT
Rh
piη6
=               1.2 
where k is Boltzmann constant (1.380x10-23 J K-1); T is temperature (K); η is viscosity (Pa s-1); 
and D is diffusion coefficient (m2 s-1).3, 49 
Instrumentation for dynamic light scattering is simple and user-friendly (Figure 1.5). In 
principle, the light provided by a laser source passes through a sample containing nanoparticles. 
If a particle in solution is in the light path, it scatters light of whose intensity is further detected 
by a photomultiplier tube detector placed either at 90º or 173º. The backscatter detector at 173º 
represented in Figure 1.5 reduces interferences given by multiple scattering and large dust 
particles. The signal from the detector is transferred to a correlator that analyzes the time profile 
of the scattered light intensity. A computer processes this information and calculates the particle 
size (as diameter, Zave) based on the decay of correlation function in time. Polydispersity (as 
polydispersity index, PDI) is calculated as well and gives the size distribution of a nanoparticle 
sample. Monodisperse samples (PDI ~ 0.1) are represented by a narrow size distribution, 
whereas polydisperse samples (PDI > 0.1) would have broad size distribution including small 
nanoparticles as well as large nanoparticles and aggregates.50 
1.2.2.2 Zeta Potential 
The nanoparticle surface charge is critical for the stability of nanoparticle emulsion. If 
two particles would have no charge on the surface, they would likely coalesce. In contrast, highly 
positive or negative charged nanoparticles would remain suspended in solution for a longer 
period of time, based on their charge repulsion. For example, the positive ions of a solvent 
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attached to the surface of a negatively charged particle in suspension forms an ionic layer called 
the Stern layer. If this particle moves, the tightly attached positive charges (Stern layer) will 
move along with the particle. However, there is a diffuse layer at a certain distance from the 
surface of a particle where charges from the solvent are stationary. 
 
 
Figure 1.5 Dynamic light scattering instrumentation. 
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capillary cell containing charged nanoparticles in suspension. Zeta potential is calculated based 
on the Henry equation (equation 1.3): 
( )
piη
ζ
µ
6
kaF
E =             1.3 
where µE is electrophoretic mobility (cm
2v-1s-1); ζ is zeta potential (mV); η is viscosity (Pa s-1); 
F(ka) is Henry’s function, approximated to 1.5 (Smoluchowski) for aqueous media and 1.0 
(Huckel) for organic media.49-51 
1.2.2.3 Morphology 
Imaging techniques such as transmission electron microscopy, scanning electron 
microscopy and atomic force microscopy are typically used for the investigation of nanoparticle 
size, shape and uniformity. Transmission electron microscopy (TEM) is a powerful imaging 
technique commonly used in nanoparticle research, offering high resolution and great detail 
about nanoparticle morphology.  It is based on the interactions of electrons generated by an 
electron gun with a thin layer of sample (≤ 100 µm) fixed on a small copper grid (3 mm).  
There are two types of electrons detected in TEM, those transmitted through the sample 
that do not interact with the sample, and those that are scattered by a more dense material. Using 
this technique, a contrast TEM micrograph is formed on a phosphorous screen by light areas of 
transmitted electrons and dark areas of scattered electrons. A condenser system controls the 
intensity of the electron beam, whereas a series of lenses are used for the increase in 
magnification up to 200,000 times.3, 52 
1.2.2.4 Drug Loading 
Drug loading refers to the amount of encapsulated drug into the polymeric nanoparticles 
at the end of the synthesis process, after the elimination of excess drug that was not encapsulated. 
The drug loading is typically expressed as encapsulation efficiency representing the ratio 
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between the detected drug amount and the drug amount calculated based on the initial quantity 
added to the formulation. The expression for encapsulation efficiency is given by equation 1.4: 
100(%) ×=
ltheoretica
calculated
drug
drug
EE             1.4 
where EE % is the encapsulation efficiency; drugcalculated is the ratio between the amount of drug 
(mg) determined using analytical methods and the amount of nanoparticles  (mg) taken for 
analysis; and drugtheoretical the ratio between the amount of drug (mg) and the amount of polymer 
(mg) added initially to the formulation. The entrapment efficiency can be directly determined by 
dissolving a known amount of nanoparticles in appropriate solvents and analyzing the drug 
content. Alternatively, one can determine loses of polymer, drug and emulsifier during the 
nanoparticle synthesis, and calculate the drug loading by the difference. 
 The amount of encapsulated drug can be determined by various methods such as 
spectroscopy and separation techniques. For example, if the drug absorbs and emits light, then 
the drug loading can be easily determined by UV-Vis and fluorescence spectroscopy, 
respectively. In general, UV-Vis spectroscopy is a useful simple technique that is easy to use 
and widely available in research laboratories. Using this method, UV light passes through a 
transparent sample of known path length, and the transmitted or absorbed light is detected. The 
concentration of an analyte can be determined using Beer-Lambert’s law as defined by equation 
1.5: 
bcA ε=              1.5 
where A is absorbance (a.u.); b is path length (cm); c is analyte concentration (M); and ε is molar 
absorbtivity (cm-1 M-1). 
For direct determination of drug loading using UV-Vis spectroscopy, scattering light 
from the nanoparticle solution represents an important limitation. In addition, polymers usually 
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absorb light as well. If there is an overlap between the absorbance of the drug and the absorbance 
of other nanoparticle components, several sample preparation steps such as precipitation and 
filtration can be taken to eliminate such interferences. However, UV-Vis spectroscopy becomes 
useful for indirect determination of drug loading. In this case, drug loses in the purification steps 
such as centrifugation can be quantified and entrapment efficiency can be calculated by the 
difference. Typically, the determination of drug concentrations in the mM range is suitable for 
UV-Vis spectroscopy.  
Fluorescence spectroscopy is a more sensitive technique in comparison to UV-Vis 
spectroscopy. When light comes in contact with a molecule in a ground state, it induces 
molecular excitation to an excited state of higher energy (excited state). The processes taking 
place in the excited state are represented by Jablonski diagram (Figure 1.6). Fluorescence (FL) 
occurs when the molecule is slowly relaxed to ground state emitting a photon that is further 
detected. 
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FL
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Figure 1.6 Jablonski Diagram representing the energy levels and processes of molecular 
excited state. FL – fluorescence; IC – internal conversion; ICX – intersystem 
crossing; PH – phosphorescence. 
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Processes such as internal conversion (IC) and intersystem crossing (ICX) are non-
radiative energy transitions. In constrast, phosphorescence (PH) is a radiative process occurring 
by relaxation from a triple excited state. The components of UV-Vis and fluorescence 
spectroscopy instrumentation are schematically represented in Figure 1.7. They include a light 
source, gratings, a sample holder and a detector. The two instruments are comparable. However, 
fluorescence spectroscopy involves two gratings and a 90º angle configuration. Therefore, 
fluorescence spectroscopy is more sensitive, and can detect concentrations in the nanomolar 
range as compared to micromolar concentrations detected by UV-Vis spectroscopy. 
 
 
Figure 1.7 Instrumentation for spectroscopic methods. A) UV-Vis Spectroscopy; B) 
Fluorescence Spectroscopy. 
 
Fluorescence spectroscopy has been used for determination of encapsulation efficiency of 
polymeric nanoparticles containing various fluorescent molecules that  have been used for 
fluorescence imaging.53 In addition, fluorescent anticancer drugs such as doxorubicin were 
encapsulated into polymeric nanoparticles, and the drug loading was determined by fluorescence 
spectroscopy.54, 55  
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Although spectroscopic techniques are useful in the determination of drug loading, 
complex matrices of nanoparticle formulations containing drugs, polymers, surfactants and other 
molecules would be difficult to analyze without preliminary sample preparation steps. In 
addition, many of the pharmaceutical compounds do not posses spectral properties, and, in some 
cases, the interferences from the polymer or other compounds present in formulation become 
significant. Instead, chromatographic separation techniques can be applied. 
High performance liquid chromatography (HPLC) is commonly used in nanoparticle 
research for determination of drug composition. Using this method, each component is separated 
based on their partition between a solid stationary phase fixed inside a chromatographic column, 
and a liquid mobile phase passing through the column. Furthermore, separated components can 
be detected by a variety of detectors including UV-Vis, fluorescence, and electrochemical 
detectors. A typical HPLC system is depicted in Figure 1.8.  
 
 
Figure 1.8  High performance liquid chromatography system. 
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The HPLC instrumentation includes the solvent containers, pumps and mixers for mobile 
phase preparation, a sample holder and injection system, the chromatographic column, and a 
detector. There are two modes that can be used for nanoparticle composition analysis: reversed 
phase and normal phase HPLC. The differences between these modes are shown in Table 1.1. In 
the reversed phase mode, stationary phase contains silica beads modified with alkyl chains of 4-
18 carbons, whereas in normal phase hydrophilic compounds are simply adsorbed on the surface 
of silica packing.  
 
Table 1.1 Differences between HPLC modes 
Mode Stationary phase Mobile phase Analytes 
Reverse phase 
Non-polar: 
Hydrocarbons (C4, 
C8, C18) 
 
Polar: water, 
alcohols, acetonitrile 
 
Non-polar (the least 
non-polar elutes first) 
Normal phase 
Polar: water, tri- 
ethylene glycol 
Non-polar: hexanes, 
isopropyl ether 
Polar (the least polar 
elutes first) 
 
The polarity of the mobile phase is opposite to the one of the stationary phase, allowing 
partitioning of the analytes between these phases. The longer the analyte interacts with the 
stationary phase, the longer the retention time would be. Therefore, a chromatogram contains fast 
eluting peaks for non-interacting compounds at shorter times as well as interactive compounds at 
longer times.56 Determination of a hydrophobic drug loading typically involves a reverse phase 
HPLC system. The selection of an appropriate solvent that allows complete nanoparticle 
dissolution is important in order to avoid further drug losses that would affect the entrapment 
efficiency. In addition, an adequate mobile phase that clearly separates all compounds present in 
the nanoparticle formulation and does not create any precipitation in the system should be used. 
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1.3 Molecular Micelles 
Many nanoparticle preparation methods are based on the formation of oil-in-water (o/w) 
nanoemulsions that require the presence of an anionic, cationic, or non-ionic surfactant 
(emulsifier) dissolved in the aqueous phase. The surfactant adsorbs on the surface of organic 
droplets based on hydrophobic interactions consequently reducing the surface tension between 
the oil and the aqueous phases. For a surface tension near zero, a spontaneous emulsion is 
formed. An important aspect is the size of an emulsion droplet that depends on various factors 
including surfactant concentration and oil to water phases’ ratio. For example, large droplets 
seem to coalesce easily while small droplets remain suspended in water for a longer period of 
time. In nanoparticle synthesis, nanoparticle size and size distribution are directly related to 
reduction and stability of emulsion droplet. Several emulsifiers such as sodium dodecyl sulfate 
(SDS), dodecyl dimethyl ammonium bromide (DMAB), poly (vinyl alcohol) (PVA), poly 
(ethylene glycol) (PEG), Pluronic, Tween, and tocopheryl polyethylene glycol succinate (TPGS) 
are used for such purposes.57-61 
1.3.1 Comparison with Conventional Micelles 
In general, surfactants are amphiphilic molecules that have both hydrophobic and 
hydrophilic groups. For example, SDS is a common anionic surfactant that has a hydrophobic 
alkyl chain (tail) and a negatively charged sulfate group as hydrophilic moiety (head). Other 
surfactants can be cationic such as DMAB, or neutral such as Triton X. In aqueous solution, 
surfactant molecules self-assemble into spherical micelles, rods and bilayers depending on the 
surfactant geometry and concentration.  
The critical micellar concentration is defined as the concentration at which a micelle is 
formed, often observed by a sudden decrease of solution surface tension.49 Micelles are in a 
dynamic equilibrium with the surfactant molecules, and any change in the environment can 
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disrupt their stability in solutions. In contrast, molecular micelles offer an advantageous 
alternative to conventional micelles, because of their enhanced stability, rigidity, and controllable 
size.62 A comparison between conventional and molecular micelles is depicted in Figure 1.9. 
Molecular micelles present a CMC value of zero, as determined by the covalently bound micellar 
core, which eliminates the dynamic equilibrium between the monomers and the micelle, 
conferring enhanced stability. It should be noted that anionic molecular micelles such as poly 
(sodium N-undecenyl sulfate) (poly-SUS), poly (sodium N-undecenyl-glycinate) (poly-SUG) and 
poly (sodium N-undecenyl-L-leucyl-valinate) (poly-L-SULV) have been successfully used as 
alternatives to conventional micelles for pseudostationary phases in chromatographic 
separations.62-64  
 
 
Figure 1.9  Comparison between conventional micelles and molecular micelles. 
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1.3.2 Molecular Micelles in Nanoparticle Synthesis 
The importance of the emulsifier in the stability of emulsion is well established. However 
in case of nanoparticles used as drug delivery systems, the bulk emulsifier is removed, mainly 
because of its toxicity. In addition, the remaining emulsifier has to be at a low concentration in 
order to avoid toxic effects, but at a high enough concentration in order to allow re-suspension of 
nanoparticles in aqueous solution after purification and drying. 
Sodium dodecyl sulfate (SDS) has also been used as an emulsifier in nanoparticle 
synthesis, and often leads to small particle sizes.41 However, the stability of nanoparticle 
suspension is affected after SDS removal, by the formation of aggregates which are not able to 
re-suspend in an aqueous solution. In addition, the surfactant is efficient as emulsifier only at 
concentrations higher than the CMC, which limits the investigation of a wider range of 
concentrations. Poly (vinyl alcohol) (PVA) is one of the commonly used emulsifiers, which leads 
to the formation of high stable nanoparticles in solution.40, 47 However, the residual PVA 
attached to the nanoparticle surface is difficult to remove and limits the nanoparticle cellular 
uptake and drug controlled release properties.65 
1.4 Antioxidants 
 Nanomedicine and drug delivery systems have a direct impact on the improvement of 
disease treatment, especially in chemotherapy. In addition, disease prevention is an important 
aspect of our lives as we eat healthy and exercise in order to avoid illness. Antioxidants play a 
significant role in both disease prevention and treatment. The word “antioxidant” is often seen in 
the supermarkets on product labels from milk, soda, shampoo, and anti-wrinkle face cream. The 
questions of what an antioxidant is and what it does after it is used often remain unanswered. The 
term antioxidant would simply imply a compound that opposes oxidation. Indeed, in the case of 
aerobic organisms, oxidation is a normal metabolic process in which energy is produced through 
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a series of reactions that involve oxidants, i.e. free radicals. However, the overproduction of 
oxidants becomes deleterious, and therefore, is counterbalanced by the presence of antioxidants 
that act either as free radical suppressors or as scavengers.66, 67 The types of free radicals and 
their roles are described in Section 1.5.  
Antioxidants such as coenzyme Q10, enzymes superoxide dismutase (SOD) and 
glutathione peroxidase (GSP) are normally produced by the body. Other antioxidants come from 
diet and include vitamins, carotenoids, and minerals. Several examples of antioxidants are shown 
in Figure 1.10.68 Natural antioxidants can be found in nuts, seed oil, vegetables, fruits spices, teas 
and animal products. Vitamin E is a generic name represented by a group of four tocopherols. 
liposoluble compounds found in fats and oils with various antioxidant activities, depending on 
their ability to donate the hydrogen from the hydroxyl group in lipid peroxidation. Flavonoids 
are another group of antioxidants found in most of the plant leaves and flowers. The presence of 
multiple hydroxyl groups determines an enhanced free radical scavenging activity. Other natural 
antioxidants, such as vitamin C (ascorbic acid) found in citrus, resveratrol found in grapes, and 
β-carotene found in carrots are also important antioxidants. Synthetic powerful antioxidants such 
as tert-butyl hydroquinone (TBHQ), 4-methoxy-2-tert-butyl phenol (BHA) and 2,6 di-tert-butyl 
p-hydroxytoluene (BHT) are hydrophobic and thermally stable, therefore used as antioxidants in 
vegetable oils. However, such compounds are strictly regulated because of their toxicity and 
more recently have been replaced with natural antioxidants. 
1.4.1 Nutrition, Disease Prevention, and Therapy 
The majority of antioxidants come from our diet. The term antioxidant is used often on 
many consumer products to label specific antioxidant benefits. The Food and Drug 
Administration (FDA) defines an antioxidant as a nutrient that possesses antioxidant activity, 
acting against free radicals. Such activity has to be supported by scientific evidence.  
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Figure 1.10  Natural and synthetic antioxidants.   
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According to FDA, a “good source of antioxidants” is represented by a group of nutrients 
including vitamin C, vitamin E and carotenoids that are present in concentrations of 10 – 20 
percent of their recommended daily intake value.69 Besides a regular diet rich in fruits and 
vegetables that provide a daily antioxidant intake, dietary supplements are a source of 
antioxidants as well. In the recent years, a dramatic increase in the use of dietary supplements 
has been observed. It is estimated that in the United States there were over 290,000 dietary 
supplements on the market in 2005, with over $20 billion in sales, vitamins and minerals 
representing 34 percent of it.70  
Phytonutrition becomes phytotherapy when a compound with nutritional value is used for 
the improvement of physiological functions.71, 72 The use of plants and foods in the treatment of 
various conditions has been known for centuries in many regions of the world.73-76 Today many 
of them are excellent sources for drug discovery. In addition, the implications of free radicals in 
the origin of disease provided an opportunity for the development of antioxidant alternative 
therapy for disease prevention and treatment. For example, antioxidants can reduce the incidence 
of cancer, help restoring the immune system, decrease the oxidation of low-density lipoprotein, 
and in some instances prevent the development of age-related cataract and macular 
degeneration.70, 77, 78 In addition, the mechanism against disease depends on antioxidants type 
and structure. For example, enzymes such as superoxide dismutase and catalase inhibit the 
formation of superoxide anion radicals and hydrogen peroxide, while glutathione peroxidase and 
vitamin E participate in the decomposition of lipid peroxides. 
1.4.2 Quinones 
Quinones refer to a group of antioxidants that typically contain a benzoquinone structure, 
although several naphtoquinones and antraquinones have also antioxidant properties. 
Ubiquinone, also named coenzyme Q10 (Q10) is a well known endogenous antioxidant present 
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in the mitochondria where participates in the respiratory chain by reacting with superoxide anion 
radical as shown in Figure 1.11.79, 80 The enzyme NADH quinone oxidoreductase (NQO1) 
catalyzes the transformation of quinone into semi-quinone radical that further accepts electrons 
from superoxide radical. Dihydroquinone is formed at the end of the cycle regenerating the 
benzoquinone. Deficiencies in Q10 and damages of mitochondrial DNA are the main cause of 
genetic mitochondrial diseases. 81, 82 Currently, the administration of Q10 supplements is the first 
of line therapy for the treatment of mitochondrial encephalomyopathies.  
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Figure 1.11 Role of coenzyme Q10 in respiratory chain. 
 
In recent years, benzoquinone-based inhibitors of NQO1 have been developed for cancer 
treatment, favored by the high concentration of this enzyme in some types of cancer as well as 
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the hypoxic conditions of the solid tumors.80, 83 Mitomycin C (Figure 12.A) is a classical NQO1 
inhibitor and has been used as chemotherapeutic agent for a variety of cancers including head, 
neck, breast and prostate. However, its lack of specificity for cancer cells accompanied by strong 
and uncontrollable side effects limit the benefits of this drug. Alternatively, a better NQO1 
substrate with reduced side effects, EOquin (Figure 12.B) is currently used for treatment of 
superficial bladder cancer. Another class of benzoquinone anticancer drugs is represented by 
benzoquinone ansamycins (Figure 12.C). They are cyclic compounds that bind to heat shock 
protein 90, one of the most abundant chaperone proteins that is overexpressed in cancer cells.84 
Numerous clinical trials involve therapy with two benzoquinone ansamycins: 17-allylamino-17-
demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxy-
geldanamycin (17-DAAG). They are used either alone or in combination with other anticancer 
drugs for the treatment of advanced solid tumors, metastatic renal carcinoma and chemotherapy 
refractory breast cancer.85  
Natural alkylated and cyclic benzoquinones found in plant extracts presented cytotoxic 
effects against various cancer cell lines.86, 87 Thymoquinone (Figure 12.D) is the major 
constituent of  Nigella sativa black seed oil, a medicinal plant from the Ranunculaceae family, 
which has been used for centuries in Africa, Europe, and Asia for treatment of many diseases 
including inflammation, asthma, hypertension, and gastrointestinal conditions. 88 Nigella sativa 
black seed oil as well as its major constituent, thymoquinone, display antioxidant properties by 
acting as free radical scavengers. 89, 90 Thymoquinone exhibits a protective antioxidant effect 
against the severe side effects caused by doxorubicin, an anticancer drug, that can generate 
congestive heart failure after chemotherapy.91, 92 Furthermore, thymoquinone is an emerging 
anticancer drug, showing cytotoxic activities for a series of cancer cell lines including colorectal, 
ovarian, leukemia, and breast cells. 93-95 
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Figure 1.12 Benzoquinone – based anticancer drugs. 
 
1.4.3 Antioxidant Delivery 
Despite their great antioxidant and anticancer activities, many antioxidants are not 
soluble in aqueous media. Their administration is limited by low dose concentrations, use of 
organic solvents, and reduced bioavailability. On the other side, their stability, specificity, 
metabolism and clearance are factors to consider after administration. In recent years, controlled 
delivery of antioxidants has allowed a new approach for cancer therapy, cardiovascular diseases, 
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neurodegenerative diseases, and ageing. 96-99 Novel antioxidant-loaded drug delivery systems 
such as polymeric nanoparticles have been identified as alternatives that should provide long-
term delivery, prevent antioxidant degradation, and increase pharmaceutical activity of such 
antioxidants.97, 99 
Several studies have reported nanoparticle-based drug delivery systems for controlled 
delivery of antioxidants, including nanoparticles for delivery of the flavonoids such as quercetin, 
and natural antioxidant ellagic-acid.100-103 Other nanoparticles were designed for the delivery of 
coenzyme Q10that improved stability and cellular uptake.104-106  In other studies, 
“nanocurcumin” was prepared using polymeric nanoparticles for controlled delivery of natural 
curcumin, with improved solubility and anticancer properties of curcumin.107, 108  
1.5 Free Radicals 
1.5.1 Oxidative Stress and Free Radicals 
The production of energy by aerobic organisms takes place by the oxidation of biological 
substrates in the presence of oxygen. The complete oxygen reduction occurs in mitochondria and 
involves a series of radical intermediates such as superoxide anion radical (•O2
-), hydroxyl 
radical (HO•), 1O2 (singlet oxygen) and non radical species, such as hydrogen peroxide (H2O2), 
as shown in Figure 1.13.66  
 
Figure 1.13  Generation of reactive oxygen species. 
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These species are collectively named as reactive oxygen species (ROS). Other species 
including reactive nitrogen species and chlorous radicals participate in oxidation reactions as 
well. Although such reactions are well controlled, sometimes incomplete substrate oxidation and 
partial oxygen reduction occur and lead to an excess of free radicals. Such excess is typically 
counterbalanced by antioxidants able to react with ROS and inactivate them.  
If an imbalance exists between the production of radical species and the level of 
antioxidants, then the organisms face the undesired situation of oxidative stress. In contrast, if 
there is an excess of antioxidants, reductive stress takes place. Figure 1.14 graphically represents 
the balance between the ROS and antioxidants, moving towards radical species in the case of 
oxidative stress and towards antioxidants for reductive stress. Excessive production of radical 
species can lead to alteration of cellular functions responsible for cardiovascular diseases, 
neurodegenerative diseases, diabetes, cancer, joint diseases, and aging.109-114  
 
 
Figure 1.14  The balance between reactive oxygen radical species and antioxidants. 
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In comparison with other radicals, hydroxyl radical is particularly dangerous. It can be 
produced at cellular levels by Fenton and Habber-Weiss reactions of hydrogen peroxide with 
transition metals such as iron and copper (1.10 and 1.11).67, 113  
•−++ ++→+ OHHOFeFeOH 3222            1.10 
•−++ ++→+ OHHOCuCuOH 222            1.11 
The hydroxyl radical has a short half-life, and is considered the most aggressive free 
radical, mainly due to its high reactivity. It is able to react with lipids, amino acids, proteins, 
DNA, and sugars at extremely high rates, leading to cell damage and even cell death.115 Other 
sources such as ozone and ionization radiation lead to hydroxyl radical generation as well. 
1.5.2 Methods for Free Radical Detection 
Numerous methods have been developed for oxidative stress detection, and are 
summarized in Figure 1.15. They are focused on the identification and quantification of the 
oxidative stress biomarkers, the determination of antioxidant activity, as well as direct or indirect 
detection of radicals.67, 109 Biomarkers are a good indication of oxidative stress, although they are 
disease specific. Many of them require long and cumbersome procedures for the exact 
assessment of oxidative stress levels, especially in the early stages of a disease. Methods for 
antioxidant quantification are based on scavenging ability of an antioxidant and enzymatic 
activity of enzymes involved in the respiratory chain, i.e. SOD, catalase, peroxidases.  
Reactive oxygen species can be directly detected by Electron Paramagnetic Resonance 
(EPR) spectroscopy, based on their electron transfer to nitroso compounds that are stable 
paramagnetic adducts. Although highly sensitive, EPR is limited by the stability of adducts and 
instrumentation accessibility. Alternatively, fluorescence spectroscopy is a highly sensitive 
method used for the detection of reactive oxygen species (ROS). In the literature, fluorescent 
dyes have been given extensive attention for ROS indirect detection.116-118 
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Figure 1.15  Methods of detection for oxidative stress. 
 
1.5.3 Free Radical Fluorescent Sensors 
Compared to other methods, fluorescence sensors are promising tools providing several 
advantages such as high specificity, localized information at the target site, spectral and 
microscopical detection. A list of common fluorescent probes and the radicals they react with is 
presented in Table 1.2. Several dihydro-probes, including 2’7’-dichlorodihydro-fluorescein, 
dihydro-rhodamine and dihydro-calcein are used for total ROS determination, mainly because 
they are not specific for a particular radical.119  
Other more specific fluorophores such as hydroethidine were used for the detection of 
superoxide anion radical. Hydroxyl radical can be detected by hydroxylation reaction of aromatic 
compounds. Specifically, coumarin 3-carboxylic acid (C3C) has been used as fluorescent sensor 
for detection of hydroxyl radical. This probe reacts with hydroxyl radical and undergoes 
hydroxylation at position C7 of the coumarin structure, producing a highly fluorescent 
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compound, 7-hydroxy coumarin 3-carboxylic acid.120-122 Because C3C has an available 
carboxylic group in the C3 position, it can be easily coupled with other groups via peptide bond 
synthesis. Therefore, other coumarin derivatives such as the succinimidyl ester of C3C, 
phospholipid liked coumarins, and C3C – derivatized amino acids and peptides were used for the 
detection of hydroxyl radicals.123-125 
 
Table 1.2  Free radical fluorescent sensors 
Fluorophore 
•
O2
-
 
1
O2 OH
•
 H2O2 
Hydroethidine  √    
1,3-Diphenylisobenzofuran  √ √   
Homovanillic acid     √ 
2,7-Dichlorodihydrofluorescein diacetate    √ √ 
Dihydrorhodamine 123     √ 
N-Acetyl-3,7-dihydroxyphenoxazine     √ 
9,10-Dimethylanthracene   √   
2-[6-(4V-amino)phenoxy-3H-xanthen-3-on-9-yl] benzoic acid    √  
Coumarin-3-carboxylic acid    √  
 
Although fluorescent probes can be used to detect hydroxyl radicals, several limitations 
should be taken into consideration. For example, the changes in the fluorescence intensity of a 
single fluorophore that reacts with a specific radical can be affected by variations in radical and 
probe concentrations, instrumental artifacts and environmental factors such as temperature and 
pH. In addition, in vitro imaging becomes challenging if the probe reacts with molecules present 
in the cellular media,  photobleaches or generates other secondary radicals.126 A novel approach 
for detection of hydroxyl radicals is the use of fluorescence ratiometric detection that likely 
eliminates such limitations. In this case, the intensity ratio of two probes is directly proportional 
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with analyte concentration independently of aforementioned factors. Such ratiometric fluorescent 
sensors were reported for the detection of hydrogen peroxide and hydroxyl radicals using 
coumarin-coupled dyes.127, 128 An alternative approach is the use of ratiometric nanoparticles. In 
Chapter 4 of this dissertation, ratiometric PLGA nanoparticles were used for the detection of 
hydroxyl radicals. The reporting signal is given by a coumarin-functionalized molecular micelle 
while the reference signal is given by neutral red loaded nanoparticles. 
1.6 Chemometrics and Optimization Design 
Chemometrics is a relatively new discipline developed only 30-35 years ago along with 
the advances in computing, fast data collection and the increasing importance of analytical data 
in industry. Chemometrics simply refers to analysis and interpretation of instrumental data. For 
examples, the optimum conditions of a chemical reaction are found by analyzing the effects of 
reagent concentrations and environmental reaction conditions on the yield of products. In 
chromatographic separation of various pharmaceuticals pattern recognition defines groups of 
compounds from the same origin. In addition, chemometric approaches facilitate the 
spectroscopic quantification of reagents and products of a chemical reaction or the components 
of a complex biological sample. 
It is always advantageous to plan and design experiments ahead of time. Using this 
approach, four major components of experimental design can be defined as follows:129 
1) Screening. A large number of parameters such as concentration of reagents, 
temperature, and pH can be investigated in order to identify the most important ones.  
2) Optimization. The truly optimum conditions of a chemical process can be found. For 
example, the highest yield of a reaction was found 80 % for a temperature of 20 ºC, at 
a pH of 7. However, applying an optimization design, the reaction yield was found 95 
% at a temperature of 30 ºC and a pH of 6.  
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3) Time saving. As an expansion of small scale screening and optimization, time saving 
becomes important on an industrial scale where the relationships between structures 
and measured properties must be quantified in real time. 
4) Quantitative modeling. Based on collected experimental data and chemometric 
analysis, models can be developed and predict future experiments.  
In the process of experimental design, one establishes factors – the input controllable 
parameters – such as pH, temperature, and concentration, and measures the responses – the 
output parameters – such as yield, resolution, efficiency. These factors can be investigated at 
different levels denoted negative for the lowest, zero for the middle and positive for the 
highest.130 The response can be described in a simple case by equation 1.12 where it strictly 
depends on one factor and defined as single linear regression. In case of multiple interactions, the 
response can be described by a multi-linear regression given by equation 1.13. 
bxby += 0               1.12 
nn xbxbxbby ++++= ...22110            1.13 
where  y is the response;  xn are the factors; b0 is the intercept; and bn are the coefficients that 
indicate the extent of x-y dependency. the goal of an experimental design being to find the 
coefficients b and a matrix D containing all factors and responses. In addition, a model is defined 
based on the experimental data and it is able to predict the response as a function of investigated 
factors. 
 There are several optimization experimental designs commonly used by chemists. They 
are graphically represented in Figure 1.16. Factorial design is the simplest design and usually 
used for screening in order to find the main factors that affect the response. A more 
comprehensive optimization design is the central composite design. This design includes a 
factorial design and a star design that allows the investigation of both linear and quadratic 
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factors. Another useful design is represented by Box-Behnken design in which the levels of the 
investigated factors are central as compared to positive and negative levels used by the other 
designs. This allows for a reduced number of experiments, consequently reducing the time, but 
maintaining the benefits of an experimental design. Both central composite and Box-Behnken 
designs include central samples for reproducibility purposes, where all factors are set at level 
zero. 
   
Figure 1.16  Types of optimization designs. 
 
In nanoparticle synthesis, optimization experimental design is an extremely useful 
tool.131-135 In many nanoparticle formulations, factors such as polymer concentration, drug 
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Therefore, it is important to strictly control such factors in order to obtain the desired particle 
size, polydispersity, and drug entrapment efficiency.  
1.7 Scope of Dissertation 
Polymeric nanoparticles are useful tools in drug delivery and nanomedicine. In particular, 
polymeric nanoparticles modified with various molecular micelles offer advantages in terms of 
particle size and polydispersity control, as well as properties related to biological and analytical 
purposes. A general description of nanoparticle synthesis and characterization methods is 
presented in the first chapter of this dissertation. In addition, the roles of antioxidants and free 
radicals in nutrition and disease prevention are described. The use of polymeric nanoparticles for 
delivery of antioxidants as well as the detection methods for free radicals are introduced in 
Chapter 1 as well. 
In the second chapter of this dissertation, a chemometric central composite experimental 
design (CCD) was used to optimize the synthesis of poly (D,L lactide-co-glycolide) (PLGA) 
nanoparticles by emulsification solvent evaporation using anionic molecular micelles, such as 
poly (sodium N-undecenyl sulfate) (poly-SUS), poly (sodium N-undecenyl-glycinate) (poly-
SUG) and poly (sodium N-undecenyl-L-leucyl-valinate) (poly-L-SULV) as well as conventional 
emulsifiers, such as anionic sodium dodecyl sulfate (SDS) and non-ionic poly (vinyl alcohol) 
(PVA). The individual and combined effects of PLGA concentration, emulsifier concentration, 
homogenization speed, and sonication time (design variables) on particle size and polydispersity 
index (responses) were investigated using multivariate analysis.  A quadratic model was used to 
predict the properties of molecular micelle - modified PLGA nanoparticles demonstrating the 
advantage of using optimization design in the synthesis of polymeric nanoparticles. 
Molecular micelle – modified PLGA nanoparticles were used for the delivery of 
thymoquinone, an antioxidant and anticancer drug. In the third chapter of this dissertation, 
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anionic amino acid - based molecular micelles were used as emulsifiers in the synthesis of 
thymoquinone (TQ) – loaded PLGA nanoparticles by use of an emulsification solvent 
evaporation method.  The optimum TQ entrapment efficiency was found for  poly-SUG – 
modified PLGA nanoparticles using a Box-Behnken experimental design.  In addition, other 
structurally related molecular micelles having various amino acid head groups and different 
hydrophobic carbon chain lengths were also examined as emulsifiers. Furthermore, other 
properties of TQ-loaded nanoparticles were investigated, including drug release, total antioxidant 
activity, and cytotoxicity against breast normal and cancer cells. 
Molecular micelle – modified polymeric nanoparticles can be used not only for delivery 
of antioxidants, but as analytical nanosensors for detection of free radicals. In Chapter 4 of this 
dissertation, neutral red (NeR) loaded PLGA nanoparticles were synthesized by emulsification 
solvent evaporation using molecular micelles such as poly (sodium N-undecenyl-Nε-lysinate) 
(poly-Nε-SUK) functionalized with coumarin 3-carboxylic acid (C3C) as emulsifier. Such 
nanoparticles   were able to detect hydroxyl radicals based on a ratiometric fluorescence 
detection scheme. The product of the reaction between the coumarin functionalized molecular 
micelle and  hydroxyl radicals, 7-hydroxy coumarin 3-carboxylic acid (7-OH C3C) represented 
the reporting dye, while NeR was the reference dye. C3C-poly-Nε-SUK – modified NeR-loaded 
nanoparticles were able to detect hydroxyl radicals in simulated samples as well as biological 
samples exposed to oxidative stress. 
The research presented in this dissertation demonstrates the utility of molecular micelles 
in nanoparticle synthesis, their versatility that conferred tunable properties for drug loaded 
nanoparticles, and their ability to offer functional groups for analytical purposes. Molecular 
micelle – modified nanoparticles are not only an example of drug delivery systems, but 
nanosensors that can be used for detection of various molecules. 
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CHAPTER 2 
EXPERIMENTAL DESIGN AND MULTIVARIATE ANALYSIS FOR OPTIMIZING 
POLY (D,L-LACTIDE-CO-GLYCOLIDE) (PLGA) NANOPARTICLE SYNTHESIS 
USING MOLECULAR MICELLES
*
 
 
2.1 Introduction 
Significant advances in the application of nanotechnology in the medical field have been 
recently witnessed, particularly relevant to the improvements in pharmaceuticals’ bioavailability 
and delivery. Controlled drug delivery systems offer an excellent alternative to the free drug 
administration, providing a constant drug concentration in the bloodstream within the efficient 
therapeutic range, for a prolonged period of time. The benefits of such systems include a reduced 
number of doses, minimizing the undesirable side effects and adverse reactions, leading to 
improved general comfort of the patient.
1-3
 
Biodegradable polymeric nanoparticles are attractive drug delivery systems because of 
their biocompatibility and degradation through normal metabolic pathways, the wide variety of 
preparation methods, high encapsulation efficiency, and sustained drug release in time. 
Numerous pharmaceutical compounds can be delivered via various routes by use of 
nanoparticles. For example, the active agent can be entrapped in the polymeric matrix 
(nanospheres), encapsulated into a nanocapsule structure, and adsorbed or chemically bound to 
the nanoparticle surface.
4-6
 Using this variety of approaches, polymeric nanoparticles have been 
extensively investigated as delivery systems in cancer therapy,
7, 8
 gene therapy,
9
 and protein 
delivery.
10
 Poly (lactic acid), poly (glycolic acid) and their copolymer poly (lactide-co-glycolide) 
(PLGA) are the most commonly used biocompatible and biodegradable polymers in the 
preparation of nanoparticle drug carriers.
11, 12
 Various methods are available for polymeric 
nanoparticle synthesis, including emulsification solvent diffusion, dialysis, salting-out, and 
                                                 
*
 Reproduced with permission from Journal of Nanoscience and Nanotechnology (Appendix V) 
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nanoprecipitation.
13-15
 Emulsification solvent evaporation is commonly used for the preparation 
of polymeric nanoparticles, where either a single oil-in-water (O/W) emulsion is prepared for the 
entrapment of hydrophobic active agents 
16-21
 or, a double water-in-oil-in-water (w/o/w) 
emulsion is used for the encapsulation of water soluble active agents.
22, 23
 
Nanoparticle synthesis is a challenging process involving many variables which affect the 
nanoparticle physico-chemical properties relevant to the performance of polymeric nanoparticles 
as drug delivery systems. For example, particle size, polydispersity, and surface charge are 
critical characteristics for the biological applications of polymeric drug carriers.
24, 25
 
Chemometric experimental design is an emerging field in nanoparticle synthesis which can be 
employed for the evaluation of individual effects as well as combined effects of the preparation 
variables on the nanoparticle characteristics. The influence of polymer concentration, emulsifier 
type and concentration, phase ratio, and drug concentration is typically studied on particle size, 
size distribution, surface properties, entrapment efficiency, and drug release properties.
26-30
 By 
use of chemometric experimental design with a reduced number of experiments one can establish 
the optimal conditions which lead to the desired characteristics of polymeric nanoparticles. 
Central composite design is an excellent choice for nanoparticle synthesis in comparison to other 
experimental design approaches, such as full or fractional factorial designs, because of its ability 
to provide the linearity as well as the curvature of the responses as a function of the design 
variables.
27, 28
 
Many nanoparticle preparation methods involve the presence of an anionic, cationic, or 
non-ionic emulsifier dissolved in the aqueous phase. The role of the emulsifier is typically to 
stabilize the emulsion and consequently to reduce the particle size and improve the size 
distribution. Poly (vinyl alcohol) (PVA) is one of the commonly used emulsifiers which leads to 
the formation of nanoparticles with a small size.
16, 23
 However, the residual PVA attached to the 
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nanoparticle surface is difficult to remove and limits the nanoparticle cellular uptake and drug 
controlled release properties 
31
. Sodium dodecyl sulfate (SDS) has also been used as an 
emulsifier in nanoparticle synthesis, and often leads to small particle sizes. However, the stability 
of nanoparticle suspension is affected after SDS removal, by the formation of aggregates which 
are not able to re-suspend in an aqueous solution.
17
 In certain cases, the surfactant emulsifier is 
efficient only at concentrations higher than the critical micelle concentration (CMC), which 
limits the investigation of a wider range of concentrations.  
Molecular micelles offer an advantageous alternative to conventional micelles, such as 
SDS, because of their enhanced stability, rigidity, and controllable size
32
 Furthermore, molecular 
micelles present a CMC value of zero, as determined by the covalently bound micellar core, 
which eliminates the dynamic equilibrium between the monomers and the micelle. Thus, the 
formation of monodispersed polymeric nanoparticles may be achievable at a low emulsifier 
concentration, using molecular micelles. It should be noted that anionic molecular micelles such 
as poly (sodium N-undecenyl sulfate) (poly-SUS), poly (sodium N-undecenyl-glycinate) (poly-
SUG) and poly (sodium N-undecenyl-L-leucyl-valinate) (poly-L-SULV) have been successfully 
used as alternatives to conventional micelles for pseudostationary phases in chromatographic 
separations.
32-34
 
In this study, we report the use molecular micelles as potential emulsifiers in the 
synthesis of polymeric nanoparticles.
35
 The first objective of the present study was to synthesize 
PLGA nanoparticles using three molecular micelles (poly-SUS, poly-SUG and poly-L-SULV) 
and two conventional emulsifiers (SDS and PVA) by use of the emulsification solvent 
evaporation method. Secondly, an investigation of the effect of four formulation parameters 
(design variables) on particle size and size distribution (responses) was performed using a central 
composite experimental design (CCD) and multivariate analysis. The design variables used in 
 46 
this study were PLGA concentration, emulsifier concentration, homogenization speed, and 
sonication time. In addition, the experimental values of selected formulations for each emulsifier 
were compared with the predicted values given by the model. Finally, the optimal experimental 
conditions were selected based on CCD, in order to synthesize PLGA nanoparticles having the 
minimum particle sizes and minimum PDI values. The optimal nanoparticle suspensions were 
further purified by use of dialysis and then freeze-dried.  The changes in their physico-chemical 
properties such as particle size, polydispersity index (PDI), and zeta potential were monitored 
before dialysis, after dialysis, and after freeze-drying. The morphology of the dried PLGA 
nanoparticles prepared with molecular micelles as emulsifiers was investigated using 
transmission electron microscopy (TEM). 
2.2 Experimental 
2.2.1 Materials 
Poly (D,L-lactide-co-glycolide) (PLGA, lactide:glycolide 50:50, MW 40,000-75,000), 
poly (vinyl alcohol) (PVA, average MW 9,000-10,000, 80 % hydrolyzed), sodium dodecyl 
sulfate (SDS), undecylenic acid, ω-undecylenyl alcohol, glycine, ethyl acetate, hydrochloric 
acid, chlorosulfonic acid, sodium carbonate, and sucrose were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). N-hydroxysuccinimide (NHS), N,N’-dicyclohexylcarbodiimide (DCC), 
and pyridine were purchased from Fluka (Milwaukee, WI, USA). Isopropyl alcohol, 
tetrahydrofuran, and ethyl ether were purchased from EMD Chemicals Inc. (Gibbstown, NJ, 
USA). LL-leucyl-valinate was purchased from Bachem Bioscience Inc. (King of Prussia, PA, 
USA). Sodium bicarbonate and sodium hydroxide were purchased from Fisher Scientific 
(Pittsburgh, PA, USA). Butyl alcohol was purchased from Mallinckrodt (Hazelwood, MO, 
USA). Doubly-distilled deionized water was obtained from an ELGA PURELAB Ultra water 
polishing system (US Filter, Lowell, MA, USA).  
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2.2.2 Synthesis of Molecular Micelles 
A sulfate based molecular micelle, poly (sodium N- undecenyl sulfate) (poly-SUS), was 
prepared according to Bergstrom’s procedure 
36
, modified by Shamsi et al.
37
 A general synthesis 
scheme is presented in Appendix I. The micelles poly (sodium N- undecenyl-glycinate) (poly-
SUG) and poly (sodium N- undecenyl-L-leucyl-valinate) (poly-L-SULV) were synthesized 
according to the procedure described by Macossay et al.
38
 The chemical structures of the 
molecular micelles are presented in Figure 2.1. 
2.2.3 Nanoparticle Synthesis 
PLGA nanoparticles were synthesized by use of an emulsification solvent evaporation 
method. Briefly, appropriate amounts of PLGA were dissolved in 2.5 mL ethyl acetate to form 
an organic phase. The aqueous phase was prepared by dissolving various amounts of emulsifiers, 
molecular micelles (poly-SUS, poly-SUG and poly-L-SULV) or conventional surfactants (SDS 
and PVA), in 10 mL water. The organic phase was then added dropwise to the aqueous phase 
under stirring conditions using a homogenizer (model 398, Biospec Products, Inc., Racine, WI, 
USA) at different speeds, resulting in a single o/w emulsion.  The emulsion droplets were further 
reduced by sonication using a probe ultrasound processor (model VC750, Sonics and Materials 
Inc., Newton, CT, USA), operating at an amplitude intensity of 30 %, for periods of time ranging 
from 5 minutes to 20 minutes. The solvent was evaporated using a rotary evaporator 
(Büchirotovapor R-200, Brinkmann Instruments, Inc., Westbury, NY, USA).  
2.2.4 Central Composite Experimental Design and Multivariate Analysis 
The effects of four design variables on particle size and size distribution were 
simultaneously investigated using a central composite design (CCD). The design variables were 
the PLGA concentration, stabilizer concentration, homogenization speed, and sonication time. 
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All other parameters were held constant. The CCD and resultant data analysis were performed 
using Unscrambler 9.1.2 software (Camo, Corvallis, OR, USA, version 9.1.2) 
 
HN
O
NH
O
n
CH2CH(CH3)2
O-Na+
O
(H3C)2HC
HN
O
O
-
Na+
O
n
OSO3
-
Na+
n
(A) (B) (C)  
Figure 2.1 Chemical structure of investigated molecular micelles. (A) poly (sodium N-
undecenyl sulfate) (poly-SUS); (B) poly (sodium N- undecenyl-glycinate) (poly-
SUG); (C) poly (sodium N- undecenyl-leucyl-valinate) (poly-L-SULV). 
 
The optimal experimental conditions necessary to synthesize PLGA nanoparticles having 
the minimum particle sizes and minimum PDI values were determined by use of CCD for each 
of the investigated emulsifiers.  The levels of the investigated design variables are presented in 
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Table 2.1. The experimental design involved a total of 29 experiments, with 5 central level 
samples to evaluate the reproducibility of the nanoparticle synthesis.  
 
Table 2.1 Levels of design variables investigated in the central composite design 
 
Design Variable Levels 
PLGA concentration (% (w/v)) 0.5 2.0 3.5 5.0 6.5 
Emulsifier concentration (% (w/v)) 0.05 0.1 0.55 1.0 1.5 
Homogenization speed (rpm) 5,000 10,000 15,000 20,000 25,000 
Sonication time (min) 0 5 10 15 20 
 
2.2.5 Nanoparticle Purification 
In order to verify the changes in particle size and PDI after synthesis, the optimal 
formulations were further purified by dialysis and freeze-dried. The PLGA nanoparticle 
suspension was introduced in a Spectra/Por Float-A-Lyzer tube (cellulose ester membrane, 
MWCO 100,000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA) prepared 
according to the manufacturer’s instructions and placed in a 4 liter volume of water under 
magnetic stirring for 24 hours (the external water was completely replaced after 12 hours). 
Dialyzed nanoparticle suspensions were further lyophilized (Freezone Plus 6, Labconco, Kansas 
City, MO, USA) in the presence of 2 % (w/v) sucrose as a cryoprotectant. The dried 
nanoparticles were re-suspended in water at 0.1 % (w/v) concentration for the investigation of 
their physico-chemical properties. 
2.2.6 Nanoparticle Characterization 
The average particle diameter (Zave) and size distribution indicated by the polydispersity 
index (PDI) were measured by use of dynamic light scattering (DLS) (Zetasizer NanoZS, 
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Malvern Instrumets Ltd., Malvern, UK) and reported as intensity distribution. For each 
measurement, appropriate volumes of nanoparticle suspension were transferred into a disposable 
polystyrene cuvet for particle size and PDI determinations. Nanoparticle surface charge indicated 
by zeta potential was measured by use of laser doppler anemometry (Zetasizer NanoZS, Malvern 
Instrumets Ltd., Malvern, UK) using a capillary cell. The reported values of particle size, PDI, 
and zeta potential represent an average of 3 measurements performed at 25 ºC, for each batch of 
nanoparticle suspensions. The nanoparticle morphologies were investigated using transmission 
electron microscopy (TEM) (JEOL 100CX, JEOL USA Inc., Peabody, MA, USA) operating at 
80kV. A drop of nanoparticle suspension was dried at room temperature on a carbon coated 
copper grid and negatively stained with a 2 % uranyl acetate solution, to create a contrast image, 
prior to imaging. 
2.3 Results and Discussions 
2.3.1 Optimization of Nanoparticle Synthesis 
In the present study, PLGA nanoparticles were synthesized by use of an emulsification 
solvent evaporation method using molecular micelles poly-SUS, poly-SUG and poly-L-SULV as 
well as conventional emulsifiers (SDS and PVA). In aqueous solution, micelles self-assemble 
into spherical shape structures having a hydrophobic core and a hydrophilic surface formed by 
functional head groups. Polymerization of such species produces molecular micelles 
32
.  
The proposed mechanism of nanoparticle synthesis using molecular micelles is 
schematically represented in Figure 2.2. The PLGA polymer is first dissolved in an organic 
phase. The water soluble molecular micelles contribute to the formation of dispersed organic 
droplets containing PLGA, under homogenization and sonication conditions. After formation of 
an emulsion, the organic solvent is evaporated and the PLGA nanoparticles are purified and 
freeze-dried as previously described in the experimental section. 
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Figure 2.2 Proposed mechanism of PLGA nanoparticle formation by use of emulsification 
solvent evaporation using molecular micelles as emulsifiers. 
 
The results of nanoparticle synthesis using SDS, PVA, poly-SUS, poly-SUG and poly-L-
SULV under various experimental conditions are presented in Table 2.2. The experimental 
conditions for all experiments used in central composite design are listed in Appendix II. A 
multivariate analysis in the form of a multilinear regression (MLR) was used to correlate the 
nanoparticle synthetic parameters (design variables) with the nanoparticle size and PDI 
(responses). MLR was used for regression modeling since no colinearity was found between the 
design variables used in this study. In addition, the number of design variables (4) was smaller 
than the experimental runs (29). 
PLGA dissolved in 
organic solvent 
Molecular micelles in 
aqueous solution 
Homogenization  
Sonication 
PLGA nanoparticles coated 
with molecular micelles 
+ 
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Table 2.2 The responses (particle size and PDI) used in the central composite design 
 
SDS PVA Poly-SUS Poly-SUG Poly-L-SULV 
Exp. 
No. 
Zave 
(nm) 
PDI 
Zave 
(nm) 
PDI 
Zave 
(nm) 
PDI 
Zave 
(nm) 
PDI 
Zave 
(nm) 
PDI 
1 48.8 0.140 162.3 0.047 125.0 0.125 85.4 0.113 143.0 0.114 
2 52.2 0.122 162.3 0.042 115.0 0.098 84.4 0.149 113.0 0.128 
3 55.4 0.145 137.7 0.051 115.0 0.148 78.0 0.106 121.0 0.123 
4 56.3 0.145 131.0 0.039 114.0 0.114 90.1 0.148 117.0 0.120 
5 47.9 0.393 112.3 0.049 69.3 0.142 66.2 0.162 77.7 0.172 
6 44.8 0.242 115.0 0.042 101.0 0.102 66.9 0.137 89.9 0.153 
7 65.2 0.117 290.7 0.175 129.0 0.075 122 0.061 136.0 0.067 
8 54.1 0.112 158.7 0.035 115.0 0.130 88.9 0.082 144.0 0.133 
9 60.5 0.132 369.0 0.246 153.0 0.063 185.0 0.192 156.0 0.069 
10 46.6 0.178 168.0 0.044 113.0 0.128 99.6 0.117 122.0 0.122 
11 61.8 0.137 194.0 0.022 140.0 0.097 115.0 0.111 142.0 0.122 
12 61.7 0.131 322.0 0.178 155.0 0.065 158.0 0.073 145.0 0.077 
13 47.0 0.181 139.0 0.038 117.0 0.129 85.9 0.123 122.0 0.141 
14 72.7 0.138 274.3 0.188 169.0 0.105 200.0 0.110 167.0 0.069 
15 53.7 0.124 158.7 0.028 108.0 0.103 90.9 0.096 105.0 0.109 
16 50.3 0.130 174.3 0.035 108.0 0.124 95.2 0.101 123.0 0.113 
17 51.4 0.145 172.0 0.053 111.0 0.111 102.0 0.117 129.0 0.119 
18 2530.0 1.000 664.0 0.590 548.0 0.736 719.0 0.811 2130.0 0.971 
19 54.8 0.173 123.7 0.043 103.0 0.127 66.3 0.121 114.0 0.125 
20 51.8 0.132 177.3 0.027 109.0 0.140 90.6 0.097 125.0 0.117 
21 45.4 0.180 115.7 0.035 89.0 0.158 69.3 0.134 107.0 0.133 
22 80.0 0.151 402.7 0.279 162.0 0.075 155.0 0.078 171.0 0.068 
23 51.2 0.140 182.7 0.027 112.0 0.125 89.5 0.098 121.0 0.117 
24 56.5 0.157 308.3 0.194 124.0 0.081 126.0 0.059 128.0 0.054 
25 97.4 0.142 445.0 0.297 173.0 0.097 156.0 0.085 157.0 0.084 
26 50.8 0.261 134.7 0.026 91.7 0.155 63.8 0.125 130.0 0.124 
27 50.6 0.158 177.7 0.039 114.0 0.118 86.8 0.104 124.0 0.104 
28 92.4 0.126 627.0 0.330 168.0 0.061 165.0 0.081 186.0 0.082 
29 85.8 0.124 400.7 0.308 159.0 0.090 146.0 0.089 172.0 0.072 
Note: H. speed – homogenization speed; S. time – sonication time. 
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Both the linear regression and quadratic regression models were developed for 
nanoparticle synthesis. Better regression models were obtained using quadratic regression. 
Hence, the quadratic model was used for data analysis. The quadratic regression equation used 
for correlation between design variables and responses is described by equation 2.1, i.e. 
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where y is the measured response, particle size (Zave, nm), or PDI; X1 is the PLGA concentration 
(% (w/v)); X2 is the emulsifier concentration (% (w/v)); X3 is the homogenization speed (rpm); X4 
is the sonication time (minutes); b0 is the intercept; b1-4 are the regression coefficients for the 
linear terms; b12, 13, 14, 23, 24, 34 are the regression coefficients describing the interactions between 
two variables;  and b11-44 are the regression coefficients for the quadratic terms. 
Analysis of variance (ANOVA) was further used to evaluate the levels of significance of 
each design variable and their interactions on the responses. The design variables were 
considered significant for a p-value ≤ 0.05. The p-values obtained from ANOVA and the 
regression coefficients of the design variables were calculated and are listed in Table 2.3 as an 
example for particle size in case of molecular micelles. X1 is PLGA concentration (% (w/v)); X2 
is emulsifier concentration (% (w/v)); X3 is homogenization speed (rpm); X4 is sonication time 
(min). A complete  ANOVA analysis is presented in Appendix III. Generally, PLGA 
concentration and emulsifier concentration were found to be the most significant variables 
influencing the particle size and size distribution. The other two variables, homogenization speed 
and sonication time, had comparatively higher p-values, indicating less influence on the 
responses (particle size and PDI). However, for a small homogenization speed and a sonication 
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time of zero, the responses were significantly higher than the other formulations used in the 
experimental design. 
2.3.1.1 Factors Affecting Particle Size 
Particle size is an important characteristic of polymeric nanoparticles. Small 
nanoparticles are suitable for oral and parenteral administration and have better cellular uptake.
9, 
13
 In this study, the particle size was found to be dependent on the emulsifier type as well as the 
investigated formulation parameters. 
 
Table 2.3 Results of analysis of variance for particle size (molecular micelles) 
 
Particle size (Zave) 
 Poly-SUS Poly-SUG Poly-L-SULV 
Design 
variables 
p 
value 
regression 
coefficients 
p 
value 
regression 
coefficients 
p 
value 
regression 
coefficients 
Intercept 0.00 126.14 0.00 134.69 0.00 139.01 
X1 0.00 8.77 0.00 5.47 0.00 9.94 
X2 0.00 -52.20 0.00 -76.95 0.00 -49.84 
X3 0.83 0.00 0.25 0.00 0.12 0.00 
X4 0.01 -1.35 0.00 -1.54 0.00 -1.99 
X1X2 0.44 -1.60 0.51 1.34 0.59 -0.54 
X1X3 0.70 0.85 0.32 2.24 0.15 -1.76 
X1X4 0.29 2.16 0.05 4.32 0.00 4.01 
X2X3 0.49 -1.43 0.79 -0.53 0.00 3.77 
X2X4 0.26 2.15 0.03 4.55 0.00 -4.40 
X3X4 0.32 1.99 0.18 2.79 0.06 2.23 
X1
2 
0.49 -1.19 0.63 0.86 0.01 -2.80 
X2
2 
0.00 9.70 0.00 10.72 0.00 10.75 
X3
2 
0.80 0.44 0.09 3.21 0.37 0.79 
X4
2 
0.12 2.98 0.03 4.68 0.45 0.78 
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When SDS was used as the emulsifier, a particle size below 100 nm was obtained. In 
contrast, the particle size was always higher than 100 nm in the experiments using PVA. 
Comparatively, the nanoparticle synthesis using molecular micelles as emulsifiers, resulted in 
nanoparticles with sizes larger than the ones obtained using SDS, but smaller than those obtained 
using PVA. Among the three investigated molecular micelles, consistently smaller nanoparticle 
sizes were obtained with poly-SUG, followed by poly-SUS and poly-L-SULV. The reduced sizes 
obtained using molecular micelles can be explained by the self-assembling structure of molecular 
micelles in aqueous solution, having a polar group oriented to the micellar surface and a 
hydrocarbon tail within the micelle, similarly to a conventional micelle, such as SDS. However, 
the polymerized molecular micelles do not have a CMC and thus create a hydrophobic 
environment where the organic droplets can be accommodated during the homogenization and 
sonication processes. 
The response surface was further used to investigate the influence of design variables on 
particle size and size distribution. In general, comparatively smaller nanoparticle sizes were 
obtained at low PLGA concentration and at high emulsifier concentration. However, for constant 
PLGA concentration and emulsifier concentration, an increase in nanoparticle size was obtained 
at low sonication times and low homogenization speeds.  
The response surface corresponding to particle size as a function of design variables is 
represented in Figure 2.3. When SDS was used as the emulsifier (Figure 2.3.A), the minimum 
particle size range (42.4 – 54.8 nm) was obtained for PLGA concentrations below 6 % (w/v) and 
SDS concentration between 0.1 and 1.1 % (w/v). However, for an SDS concentration smaller 
than 0.1 % (w/v) and larger than 1.1 % (w/v), the particle size increased with the increase of 
PLGA concentration. The homogenization speed and sonication time, had a different effect on 
the particle size. The smallest particle size range (45.7 – 49.2 nm) was obtained for a 
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homogenization speed higher than 20,000 rpm and a sonication time higher than 10 minutes. In 
contrast, the largest particle size was obtained for a homogenization speed of 5,000 rpm and a 
sonication time of 20 minutes.  
The response surface for PVA (Figure 2.3.B) showed a minimum particle size range 
(85.5 – 172.4 nm) for a large PVA concentration range, from 0.3 to 1.5 % (w/v). However, at 
PVA concentrations below 0.3 % (w/v), the particle size increased with an increase in PLGA 
concentration. Similarly to other emulsifiers, the maximum particle size was obtained for 
emulsifier concentration smaller than 0.1 % (w/v) and PLGA concentrations higher than 5 % 
(w/v). The particle size surface response for PVA represented for homogenization speed and 
sonication time indicated a minimum particle size range (147.4 – 177.6 nm) at sonication times 
between 8 and 18 minutes, irrespective of homogenization speed. However, the particle size 
increased at low and high extremes of sonication time and homogenization speed ranges. Despite 
this flexibility, a particle size below 100 nm could not be achieved using PVA, within the ranges 
of investigated design variables. 
Similar response surfaces were obtained for the investigated molecular micelles in terms 
of PLGA concentration and emulsifier concentration (Figures 2.3.C, 2.3.D, 2.3.E). The minimum 
particle size ranges for poly-SUS (72.7 – 94.2 nm), poly-SUG (47.8 – 69.5 nm) and poly-L-
SULV (73.8 – 95.7 nm) were obtained for an emulsifier concentration between 0.5 and 1.5 % 
(w/v) and a PLGA concentration below 2 % (w/v) for poly-SUS and poly-L-SULV and below 
3.5 % (w/v) for poly-SUG. For concentrations of molecular micelles smaller than 0.5 % (w/v), 
the particle size increased and reached a maximum for a PLGA concentration higher than 5 % 
(w/v). When the particle size was represented as a function of homogenization speed and 
sonication time, the minimum particle size range was highly influenced by the type of molecular 
micelle.  In the case of poly-SUS, the minimum particle size range (105.6 – 111.7 nm) was 
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present at homogenization speeds lower than 18,000 rpm and sonication times higher than twelve 
minutes. Although poly-SUS and SDS have similar chemical structures, the strong forces 
induced in the homogenization and sonication processes seemed to disturb the equilibrium of 
SDS micelles in solution, thereby increasing the particle size. In contrast, poly-SUS micelles are 
stable micelles even at high shear forces, resulting in a minimum size range at high sonication 
times.  
 
 
Figure 2.3 Response surface corresponding to particle size for PLGA nanoparticles prepared 
with A) SDS; B) PVA C) poly-SUS; D) poly-SUG; E) poly-L-SULV (right side – 
response surface for PLGA concentration and emulsifier concentration; and left 
side – response surface for homogenization time and sonication speed). 
B) 
 
 
A) 
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Figure 2.3 Continued. 
 
 
 
E) 
 
 C) 
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In the case of poly-SUG, the minimum size range (83.6 – 92.3 nm) was achieved in the 
center of homogenization speed and sonication time ranges, i.e. 15,000 rpm and 15 minutes 
respectively. Extreme values, high or low, led to an increase in particle size. When poly-L-SULV 
was used as the emulsifier, the response surface showed a minimum range (104.2 – 112.8 nm) 
for long sonication times, between 17 and 20 minutes, and small homogenization speeds, from 
5,000 to 15,000 rpm. However, the maximum particle size range similar for all molecular 
micelles and was obtained for small homogenization speeds, below 10,000 rpm, and short 
sonication times of 5-6 minutes. 
2.3.1.2 Factors Affecting Polydispersity 
Polydispersity, represented by the polydispersity index (PDI), is an indication of the 
particle size distribution. Nanoparticle suspensions are close to monodisperse for small values of 
PDI, typically below 0.100, and they become more polydisperse as the PDI value increases over 
0.200.
28
 In the nanoparticle synthesis involving the use of SDS as an emulsifier, the experimental 
PDI values ranged from 0.122 to 0.393, while the use of PVA as an emulsifier resulted in 
nanoparticles with experimental PDI values ranging from 0.022 to 0.330. Compared to 
conventional micelles, consistently smaller PDI values were obtained when molecular micelles 
were used as emulsifiers. The smallest experimental PDI values of 0.054, 0.059 and 0.061 were 
obtained when poly-L-SULV, poly-SUG and poly-SUS were used as emulsifiers, respectively. 
Smaller experimental PDI values obtained for molecular micelles, as compared to conventional 
micelles, are probably the result of their stability and uniform size in solution, as we earlier 
hypothesized. This leads to monodisperse suspensions in all experimental formulations using 
molecular micelles as emulsifiers.  
The effect of design variables on the PDI response surface is represented in Figure 2.4. 
Although the PDI varied within a wide range, it generally decreased with a decrease of 
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emulsifier concentration and an increase in PLGA concentration. In contrast, PDI values 
decreased with a decrease of homogenization speed and an increase in sonication time. In terms 
of PLGA concentration and emulsifier concentration, the PDI produced a concave response 
surface for SDS, PVA, and the molecular micelles poly-SUG and poly-L-SULV. For the latter 
molecular micelles (Figures 2.4.D, 2.4.E), a minimum range was obtained at small emulsifier 
concentration, below 0.2 % (w/v), and PLGA concentration from 0.5 to 5.5 % (w/v). 
 
 
Figure 2.4 Response surface corresponding to polydispersity index for PLGA nanoparticles 
prepared with A) SDS; B) PVA; C) poly-SUS; D) poly-SUG; E) poly-L-
SULV(right side – response surface for PLGA concentration and emulsifier 
concentration; and left  side – response surface for homogenization time and 
sonication speed). 
 
 
 
A)  
B) 
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For SDS (Figure 2.4.A), this range was extended towards high SDS concentrations and 
high PLGA concentrations. In the case of PVA (Figure 2.4.B), the minimum PDI range was 
obtained for PVA concentrations between 0.5 and 1.5 % (w/v) and PLGA concentrations from 
0.5 to 6.5 % (w/v).  However, at PVA concentrations below 0.5 % (w/v), the PDI value increased 
with an increase of PLGA concentration. The response surface for poly-SUS (Fig. 2.4.C) was 
opposite to the ones for the other emulsifiers and seemed to be independent of PLGA 
concentration and highly dependent on poly-SUS concentration. In this case, the minimum PDI 
range was obtained for a poly-SUS concentration below 0.2 % (w/v), irrespective of PLGA 
concentration. However, for emulsifier concentration higher than 0.2 % (w/v), the PDI value 
increased with the increase of poly-SUS concentration. When the PDI response surface was 
represented as a function of homogenization speed and sonication time, the molecular micelles 
presented similar convex surfaces with a minimum situated at high homogenization speeds and 
high sonication times. The only exception was poly-L-SULV, where the minimum PDI was 
obtained for high homogenization speed (20,000 rpm), irrespective of the sonication time. In 
contrast, the PDI surface response was concave for SDS and PVA. However, the minimum range 
was located at different values of design variables. In the case of SDS, the smallest PDI values 
were obtained for homogenization speeds lower than 15,000 rpm and sonication times longer 
than fifteen minutes. For PVA, the minimum PDI range was obtained for homogenization speeds 
between 10,000 and 25,000 rpm and sonication times between 8 and 12 minutes.     
2.3.1.3 Validation of the Regression Model 
The CCD used in this study was designed to have five replicates of central samples in 
order to evaluate the reproducibility of the nanoparticle synthesis. In general, one would expect 
that the percentage relative standard deviation for particle size would be significantly smaller as 
compared to percentage relative standard deviation for PDI, simply because of their different 
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orders of magnitude. In the case of particle size, the percentage relative standard deviation of the 
five replicated central samples ranged from 1.5 % for SDS to 4.5 % for poly-SUG, indicating 
high reproducibility for the nanoparticle synthesis. In contrast, the percentage relative standard 
deviation for PDI had higher values, from 7.4 % for poly-L-SULV to 20.1 % for poly- SUG.  
In order to verify the predictive ability of the regression model, the experiments resulting 
in nanoparticles having a minimum particle size and a minimum PDI value, respectively, were 
selected for each emulsifier and reproduced in triplicate. The average values for particle size and 
PDI experimentally obtained from DLS were compared to the particle size and PDI values 
predicted by the model. The experimental and predicted values of particle size and PDI and their 
percentage relative errors are shown in Table 2.4. In general, the predictive ability of the model 
was better when molecular micelles were used as emulsifiers. Their percentage relative errors for 
particle size ranged from -7.8 % for poly-SUS to -16.1 % for poly-SUG, indicating a good 
predictability of the model for molecular micelles. In the case of the PDI values, the percentage 
relative error ranged from -3.8 % for poly-L-SULV to -23.9 % for poly-SUG. However, in the 
case of conventional emulsifiers SDS and PVA, the percentage relative errors were smaller than 
those for the PDI values of the molecular micelles, but significantly higher for the particle sizes.  
2.3.2 Characterization of Optimally Synthesized PLGA Nanoparticles 
2.3.2.1 Particle Size and Size Distribution 
PLGA nanoparticle synthesis was optimized by use of CCD. The optimal conditions 
required to synthesize PLGA nanoparticles having the minimum particle size and minimum PDI 
were selected based on the location of the minimum ranges for particle size and PDI given by the 
quadratic model. In order to verify the changes in nanoparticle physico-chemical characteristics 
after synthesis, the optimal PLGA nanoparticle formulations were further purified by dialysis 
and freeze-dried. 
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Table 2.4 Experimental and predicted particle size (Zave) and PDI 
 
Zave (nm) 
Formulation Emulsifier 
Experimental 
(n=3) 
Predicted 
% Rel. 
Error 
1S SDS 44.2 ± 0.7 49.6 12.3 
2S PVA 107.7 ± 5.0 150.9 40.2 
3S Poly-SUS 88.9 ± 10.1 82.0 -7.8 
4S Poly-SUG 79.6 ± 8.9 66.7 -16.2 
5S Poly-L-SULV 92.7 ± 24.1 79.5 -14.3 
PDI 
Formulation Emulsifier Experimental 
(n=3) 
Predicted 
% Rel. 
Error 
1P SDS 0.130 ± 0.002 0.125 -4.1 
2P PVA 0.044 ± 0.010 0.040 -7.4 
3P Poly-SUS 0.077 ± 0.021 0.059 -23.9 
4P Poly-SUG 0.071 ± 0.004 0.065 -7.4 
5P Poly-L-SULV 0.054 ± 0.004 0.066 -3.8 
Note: Formulations 1S-5S represent the optimized experiments leading to the 
minimum particle sizes; formulations 1P-5P represent the optimized 
experiments leading to the minimum PDI values. 
 
The experimental values for the particle size and the PDI values of the PLGA 
nanoparticles before dialysis, after dialysis, and after freeze-drying are provided in Figure 2.5. 
After freeze-drying, nanoparticles prepared with SDS could not be re-suspended in aqueous 
solution due to particle aggregation. However, the particle size slightly decreased after dialysis 
with a significant increase in PDI value, indicating increased polydispersity of the purified 
nanoparticles. In contrast, when molecular micelles were used as emulsifiers, the solution 
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became clearer, as the excess of molecular micelles was removed by dialysis, and the dried 
nanoparticles could be readily re-suspended in water after freeze-drying.  
 
 
Figure 2.5 Experimental particle size (A) and PDI (B) of PLGA nanoparticles before 
dialysis, after dialysis and after freeze-drying (n = 3). 1S-5S refer to optimized 
experiments leading to the minimum particle sizes; 1P-5P refer to optimized 
experiments leading to the minimum PDI values. 
 
In general, the particle size of PLGA nanoparticles prepared with molecular micelles 
increased after freeze-drying. However, we were able to obtain a particle size below 100 nm for 
freeze-dried PLGA nanoparticles using poly-L-SULV as emulsifier. In addition, the PDI values 
remained within the same range during purification for all molecular micelles, indicating a 
monodisperse nanoparticle suspension (PDI < 0.100). The nanoparticles prepared with PVA 
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were also readily re-suspended in water, their particle size and PDI values decreasing after 
dialysis and freeze-drying. 
2.3.2.2 Zeta Potential 
The value of the zeta potential for nanoparticles is an indication of suspension stability. 
An unstable suspension, where aggregates can easily form and precipitate, would have a value of 
zeta potential close to zero. High positive and low negative zeta potential values indicate a stable 
suspension because of electrostatic repulsions between charged nanoparticles. The values of zeta 
potential of synthesized PLGA nanoparticles before dialysis, after dialysis, and after freeze-
drying are presented in Table 2.5.  
 
Table 2.5  Experimental zeta potential of PLGA nanoparticles before dialysis, after dialysis 
and after freeze-drying (n=3) 
 
Zeta potential (mV) 
Formulation Emulsifier 
Before 
dialysis 
After 
dialysis 
After freeze-
drying 
1 SDS -66.3 ± 3.8 -35.8 ± 6.3 not measured 
2 PVA -2.8 ± 1.0 -27.5 ± 0.7 -29.5 ± 1.0 
3 Poly-SUS -73.1 ± 9.3 -69.5 ± 8.3 -63.2 ± 0.4 
4 Poly-SUG -69.3 ± 7.5 -67.3 ± 7.4 -61.3 ± 5.5 
5 Poly-L-SULV -65.5 ± 1.7 -63.1 ± 5.1 -54.8 ± 1.6 
   
For SDS, the zeta potential increased drastically after dialysis, as SDS was removed from 
solution, decreasing the negative surface charge of the nanoparticles. Thus, the formation of 
aggregates took place and consequently it was not possible to re-suspend the nanoparticles in 
aqueous solution, as previously noted. In contrast, when nanoparticles were synthesized using 
molecular micelles, the zeta potential remained within the same range after dialysis, slightly 
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increasing after freeze-drying to - 54 ± 1.6 mV for poly-L-SULV, - 61.3 ± 5.5 mV for poly-SUG 
and - 63.2 ± 0.4 mV for poly-SUS. This may be attributed to strong hydrophobic interactions 
between the polymer and the micelle core, the micelle remaining on the surface and intertwined 
into the nanoparticle. Therefore, the overall micellar surface charge produced a stable 
suspension, minimizing aggregation in solution after dialysis and freeze-drying. Quantitative 
methods for the determination of residual molecular micelle concentration in nanoparticle 
suspension are under development in our laboratory. Further investigation is required to 
determine the effect of the residual molecular micelle layer on the entrapment efficiency and 
release rate of active pharmaceutical compounds. When PVA was used as the emulsifier, the zeta 
potential decreased to a lower negative value after dialysis, since an excess of PVA was likely 
removed from nanoparticle surface and more negatively charged carboxylic groups of PLGA 
were uncovered. The zeta potential remained practically the same after freeze-drying, indicating 
a stable nanoparticle suspension that readily re-suspended in water.  
2.3.3 Nanoparticle Morphology 
The morphology of purified PLGA nanoparticles was investigated by transmission 
electron microscopy (TEM). The micrographs of typical nanoparticle suspension obtained with 
molecular micelles are shown in Figure 2.6. It can be noted that the particle size observed by use 
of TEM was slightly smaller than the particle size measured by dynamic light scattering. Such 
disagreement is likely determined by  the differences in the sample preparation procedures. The 
investigated nanoparticles are suspended in aqueous solution for dynamic light scattering 
measurements,  while for TEM imaging the nanoparticles are drop - casted on a grid and let dry 
before taking their image. However, spherical shape and smooth surface of the PLGA 
nanoparticles emulsified with molecular micelles were observed. In addition, no aggregates and 
precipitates were formed during the imaging process.  
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Figure 2.6 Typical micrographs of freeze-dried PLGA nanoparticles obtained with molecular 
micelles A) poly-SUS; B) poly-SUG; C) poly-L-SULV at 33,000x magnification 
(right) and 160,000x magnification (left).  
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B) 
               
 
C) 
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2.4 Conclusions 
In this study, molecular micelles were successfully used as novel emulsifiers to prepare 
PLGA nanoparticles. In addition, we were able to control the size and polydispersity of the 
PLGA nanoparticle suspension by use of a chemometric central composite design (CCD) and by 
accurate selection of optimal formulation conditions according to the CCD. The predictive 
ability of the model for particle size and PDI was better for nanoparticles obtained with 
molecular micelles in comparison with those obtained with conventional emulsifiers. 
Furthermore, after removal of excess emulsifier, the dried PLGA nanoparticles coated with 
molecular micelles were readily re-suspended in aqueous solution after purification and freeze-
drying without significant modification of their size, shape and surface charge, revealing 
promising properties as drug delivery systems.  
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CHAPTER 3 
THE EFFECT OF MOLECULAR MICELLES ON SYNTHESIS AND PROPERTIES OF 
THYMOQUINONE-LOADED POLY(D,L LACTIDE-CO-GLYCOLIDE) 
NANOPARTICLES  
 
3.1 Introduction 
Excessive production of free radical species through oxidative processes can lead to 
alteration of cellular functions responsible for cardiovascular diseases, neurodegenerative 
diseases, diabetes, cancer, joint diseases, and aging.
1-6
 The damaging effect of free radicals is 
typically counterbalanced by antioxidants acting as free radical suppressors and scavengers.
7, 8
 
Several examples enzymes such as superoxide dismutase (SOD) and glutathione peroxidase 
(GSP) as well as tocopherols,  flavonoids, polyphenols and quinones.
9
 In general, antioxidants 
play a significant role in disease prevention and treatment. The mechanism against disease 
depends on antioxidants type and structure. For example, SOD and catalase inhibit the formation 
of superoxide anion radicals and hydrogen peroxide, while GSP and vitamin E participate in the 
decomposition of lipid peroxides. In addition, antioxidants can reduce the incidence of cancer, 
improve immune system, and prevent the development of age-related cataract and macular 
degeneration. 
10-14
  
Despite their benefits, many antioxidants present poor water solubility, leading to low 
absorptivity and bioavailability. In addition, the intended therapeutic role of ingested 
antioxidants may be different than their in vivo activity once the food matrix is disrupted.
15, 16
 
Therefore, novel antioxidant-loaded drug delivery systems such as polymeric nanoparticles have 
been identified as alternatives that should provide long-term delivery at the therapeutic level, 
prevent antioxidant degradation, and increase pharmaceutical activity of such antioxidants.
17, 18
   
In recent years, controlled delivery of antioxidants has allowed a new approach for cancer 
therapy, cardiovascular diseases, neurodegenerative diseases, and ageing.
17-20
 Several studies 
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have reported nanoparticle-based drug delivery systems for controlled delivery of antioxidants. 
For example, quercetin-loaded nanoparticles have showed excellent free radical scavenging 
activity and bioavailability.
21, 22
  In addition, biodegradable nanoparticles were prepared for 
poorly soluble ellagic acid demonstrating the importance of synthetic parameters in the physico-
chemical and pharmaceutical properties of such drug delivery systems.
23, 24
 In other studies, 
“nanocurcumin” was prepared using polymeric nanoparticles for controlled delivery of natural 
curcumin with improved anticancer properties.
25, 26
 In these studies, as a result of their improved 
solubility, antioxidant loaded – nanoparticles were demonstrated to have improved antioxidant 
activity as compared with free antioxidants. 
Quinones refer to a group of antioxidants that contain typically a p-benzoquinone 
structure. Coenzyme Q10, is an lipophilic endogenous p-benzoquinone antioxidant that 
participates in the mitochondrial respiratory chain.
27, 28
 Deficiencies in Q10 and damages of 
mitochondrial DNA are the main cause of genetic mitochondrial diseases. 
29, 30
 Currently, the 
administration of Q10 supplements is the first line therapy for the treatment of mitochondrial 
encephalomyopathies. Several studies have focused on delivery of coenzyme Q10 using 
nanoparticles. Such nanoparticles enhanced drug stability and cellular uptake, providing 
promising routes for administration as compared to regular dietary supplements.
31-33
   
In the recent years, benzoquinone-based anticancer drugs have been developed as 
inhibitors of NADH quinone oxidoreductase (NQO1) involved in quinone metabolism. This 
strategy is favored by the high concentration of this enzyme in some types of cancer as well as 
the hypoxic conditions of the solid tumors.
28, 34
 Mitomycin C is a classical NQO1 inhibitor and 
has been used as chemotherapeutic agent for a variety of cancers including head, neck, breast 
and prostate. However, its lack of specificity accompanied by strong and uncontrollable side 
effects limit the benefits of this drug. Therefore there is continuous effort for the development of 
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benzoquinone drugs with improved water solubility and reduced adverse reactions. For example, 
EOquin is currently used for treatment of superficial bladder cancer, benzoquinone ansamycins 
such as 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino 
-17-demethoxy-geldanamycin (17-DAAG) alone and in combination with other anticancer drugs 
for the treatment of advanced solid tumors, metastatic renal carcinoma and chemotherapy 
refractory breast cancer.
35
 In addition, natural alkylated and cyclic benzoquinones found in plant 
extracts presented cytotoxic effects against various cancer cell lines.
36-38
  
Thymoquinone (TQ) is the major constituent of Nigella sativa black seed oil, a medicinal 
plant from the Ranunculaceae family, which has been used for centuries in Africa, Europe, and 
Asia for treatment of many diseases including inflammation, asthma, hypertension, 
gastrointestinal conditions, and skin irritations.
39
 Thymoquinone display antioxidant properties 
by acting as free radical scavengers.
40, 41
 In addition, TQ exhibits a protective antioxidant effect 
against the severe side effects caused by doxorubicin, an anticancer drug, that induces cardiac 
and renal toxicities during and after chemotherapy.
42, 43
 Furthermore, TQ is an emerging 
anticancer drug, showing cytotoxic activity for human cancer cell lines including colorectal, 
ovarian, and breast cells.
44-46
  
Although thymoquinone is a powerful antioxidant and anticancer drug, its administration 
is limited due to poor water solubility.
44, 47
 In addition, administration of high dosages to rats 
have resulted in hypoactivity and difficulty in respiration associated with reduced glutathione in 
the liver and kidney.
48
 Another report has shown that TQ is capable of reducing blood glucose 
levels and allergic dermatitis incidences.
49
 To overcome these disadvantages, biodegradable and 
biocompatible polymeric nanoparticles would be attractive alternatives for TQ delivery. Such 
nanoparticles would likely provide improved TQ solubility, controlled delivery, and enhanced 
therapeutic properties. 
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In the present study, we focused on physico-chemical properties, antioxidant activity, and 
cytotoxicity of TQ-loaded nanoparticles.  Poly(D,L lactide-co-glycolide) nanoparticles 
containing thymoquinone were synthesized by emulsification solvent evaporation method, using 
molecular micelle poly (sodium N-undecenyl-glycinate) (poly-SUG) as emulsifier. The synthetic 
parameters were investigated using a Box-Behnken experimental design in order to obtain the 
maximum entrapment efficiency. The individual and combined effects of factors such as PLGA 
amount, TQ amount and emulsifier concentration (design variables) were established on TQ 
entrapment efficiency (response).  
The surface properties of polymeric nanoparticles are influenced by the emulsifier, which 
likely plays an important role in their applications as drug delivery systems.
50
 Molecular micelles 
such as poly-SUG represent a novel class of emulsifiers used in nanoparticle synthesis. They 
have a polymerized hydrophobic core and a critical micelle concentration equal to zero that 
allow an increased stability and rigidity in comparison with conventional micelles. When used as 
emulsifiers, molecular micelles strongly interact with PLGA polymer at the organic – aqueous 
interface. Such interactions are of a hydrophobic nature and provide a reduction in the organic 
droplet size, resulting in small and monodisperse nanoparticles. Due to their charge, molecular 
micelles provide sufficient interparticle repulsions in aqueous solutions, leading to increased 
stability over time.
51
 In order to further understand the role of molecular micelles in polymeric 
nanoparticle synthesis, we investigated the properties of TQ-loaded PLGA nanoparticles 
prepared using various molecular micelles as emulsifiers. Anionic glycine-based molecular 
micelles with shorter carbon chains, poly(sodium N-heptenyl-glycinate) (poly-SHG), and 
poly(sodium N-decenyl-glycinate) (poly-SDG) were synthesized and used as emulsifiers. In 
addition, molecular micelles having various amino acid hydrophilic head groups, poly(sodium N-
undecenyl-alaninate) (poly-SUA), poly(sodium N-undecenyl-leucinate) (poly-SUL), and 
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poly(sodium N-undecenyl-valinate) (poly-SUV), were also used as emulsifiers. The effect of the 
molecular micelles was evaluated by monitoring parameters such as release profile, antioxidant 
activity, and, cytotoxicity of TQ-loaded PLGA nanoparticles. Controlled release of entrapped TQ 
was performed by use of the dialysis method under physiological conditions (pH 7.4, 37 ºC) 
using phosphate buffer as the release medium. A free-radical scavenging assay was used to 
evaluate the antioxidant activity of TQ and TQ-loaded nanoparticles prepared with various 
emulsifiers. The cytotoxicity of TQ and TQ-loaded PLGA nanoparticles were assessed using a 
breast normal cell line (Hs578Bct) and two breast cancer cell lines (hormone-dependent MCF-7 
and hormone-independent MDA-MB-231).  
3.2 Materials and Methods 
3.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA, lactide:glycolide 75:25, MW 66-107 kDa), 
thymoquinone, 2,2-diphenyl-1-picrylhydrazyl (DPPH), and sucrose were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Trolox was purchased from Acros Organics (Morris Plains, NJ, 
USA). Dibasic sodium phosphate was purchased from Mallinckrodt (Hazelwood, MO, USA). 
Dichloromethane and sodium phosphate monobasic were purchased from EMD Chemicals Inc. 
(Gibbstown, NJ, USA). All reagents were of analytical grade and used as received. 
The monomer forms of sodium N-heptenyl-glycinate (SHG), sodium N-decenyl-glycinate 
(SDG), sodium N-undecenyl-glycinate 
52
, sodium N-undecenyl-alaninate (SUA), sodium N-
undecenyl-leucinate (SUL), and sodium N-undecenyl-valinate (SUV) were synthesized and 
characterized according to our previously described procedures 
53-57
 The corresponding polymers 
were obtained via polymerization using a 
60
Co γ-irradiation source. The complete polymerization 
was confirmed by disappearance of the vinyl protons (δ ~ 6ppm) in the 
1
H NMR of the resulting 
polymers. The chemical structures of the molecular micelles used as emulsifiers in the present 
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study are represented in Figure 3.1. Molecular micelles having glycine as a hydrophilic group 
and carbon chains ranging from seven (n=3) to eleven (n=7) methylene groups are presented by 
poly-SHG, poly-SDG and poly-SUG. ). In addition, molecular micelles having the same 
hydrophobic tail and various amino acid hydrophilic head groups are represented by poly-SUA, 
poly-SUL, and poly-SUV. 
3.2.2 Cell Cultures 
Normal Hs578Bct human breast fibroblast cells (HTB-125), hormone-dependent MCF-7 
(HTB-22), and hormone-independent MDA-MB-231 (MDA, HTB-26) human mammary tumor 
cells were obtained from the American Tissue Culture Collection (ATCC, Manassas, VA) and 
grown to 90% confluence according to ATCC’s instructions. 
 
 Emulsifier n R 
 Poly-SHG 3 H 
 Poly-SDG 6 H 
 Poly-SUG 7 H 
 Poly-SUA 7 CH3 
 Poly-SUL 7 CH2CH(CH3)2 
 Poly-SUV 7 CH(CH3)2 H2C
HN
O
O
-
Na+
O
R
* *
x
n
 
    
 
Figure 3.1 Structures of molecular micelles used as emulsifiers in the nanoparticle synthesis 
(n is the length of carbon chain; x indicates the polymerization site). 
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3.2.3 Synthesis of PLGA Nanoparticles 
TQ-loaded PLGA nanoparticles were synthesized by use of an emulsification solvent 
evaporation method (single emulsion). The schematic representation of nanoparticle synthesis is 
shown in Figure 3.2. Various amounts of PLGA and TQ were dissolved in dichloromethane 
(DCM) forming an organic phase. The organic phase (1.5 mL) was dispersed into an aqueous 
phase (8 mL) containing molecular micelles using a homogenizer (model 398, Biospec Products, 
Inc., Racine, WI, USA) at 20,000 rpm for 2 minutes.  
 
Figure 3.2 Synthesis of TQ-loaded PLGA nanoparticles by emulsification solvent 
evaporation using molecular micelles as emulsifiers.  
 
The emulsion was further sonicated for 10 minutes in an ice bath using an ultrasound 
processor (25% amplitude, model VC750, Sonics and Materials Inc., Newton, CT, USA). The 
solvent was evaporated by rotary evaporation under vacuum (Büchi rotovapor R-200, Brinkmann 
Instruments, Inc., Westbury, NY, USA). The nanoparticles were precipitated by centrifugation 
Organic Phase 
PLGA + Thymoquinone 
(1.5 mL)  Drop wise 
Homogenization 
20,000 rpm 
2 min / 25 ºC 
Sonication  
25% amplitude 
10 min / ice bath 
Precipitation 
by centrifugation 
 (6,000 rpm/ 1 hour) 
Purification 
by centrifugation  
(6000 rpm/ 1 hour) 
Lyophilization 
overnight 
(2% w/v sucrose) 
Aqueous Phase  
Molecular Micelles 
(8 mL) 
Solvent evaporation 
under vacuum 
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(6,000 rpm, 1 hour) , and washed using an equal volume of water, in order to eliminate the 
excess of emulsifier and unentrapped drug. Further, the nanoparticles were lyophilized overnight 
(Freezone Plus 6, Labconco, Kansas City, MO, USA) and stored in a cool and dry environment 
until further used. In order to improve the re-suspension of TQ-loaded nanoparticles in aqueous 
media, cryoprotectant (2% w/v sucrose) was added before freeze-drying. Empty nanoparticles 
without TQ were synthesized according to the same procedure, involving an organic phase 
contained only the polymer. All other conditions were held constant. 
3.2.4 Nanoparticle Characterization  
The nanoparticle size and polydispersity (PDI) were measured using dynamic light 
scattering (Zetasizer NanoZS, Malvern Instrumets Ltd., Malvern, UK). Zeta potential was 
measured by laser doppler anemometry (Zetasizer NanoZS, Malvern Instrumets Ltd., Malvern, 
UK). Nanoparticle morphology was investigated by use of transmission electron microscopy 
(TEM, JEOL 100CX, Jeol Ltd., Peabody, MA, USA) using uranyl acetate negative staining. 
3.2.5 Thymoquinone Quantification 
The entrapment efficiency was determined by use of high performance liquid chromatography 
(HPLC, Shimadzu Scientific Instruments, Columbia, MD, USA, mobile phase 80:20 
acetonitrile:water, flow rate 0.5 mL/min, injection volume 20 µL). TQ-loaded PLGA 
nanoparticles were dissolved in the mobile phase and sonicated in a bath sonicator for sufficient 
time to ensure complete TQ solubilization. The samples were then filtered through a 0.2 µm 
syringe filter and injected into the HPLC column (Luna C18(2), Phenomenex Inc., Torrance, CA, 
USA). The entrapped TQ was quantified using the peak area for each nanoparticle formulation 
(linear range of the calibration curve was 0.1 – 0.8 mg/mL; LOD 0.0017 mg/mL). The 
entrapment efficiency (EE %) was calculated as 100 times the ratio of the entrapped TQ amount 
relative to the known amount of TQ added to each formulation.  
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3.2.6 Optimization of Entrapment Efficiency 
The influence of three synthesis parameters (design variables), PLGA amount, TQ 
amount, and poly-SUG concentration, on TQ entrapment efficiency (response) was 
simultaneously investigated using chemometric Box-Behnken experimental design. The design 
variables were investigated at three levels involving a total number of fifteen experiments 
including three replicates at the central level. The resultant data analyses were performed using 
Unscrambler 9.1.2 software. The synthesis conditions were considered optimum for formulations 
where the maximized entrapment efficiency was obtained. In addition, the influence of other 
emulsifiers such as poly-SHG, poly-SDG, poly-SUA, poly-SUL and poly-SUV on the TQ 
entrapment efficiency was further investigated employing the optimum conditions. 
3.2.7 In vitro Controlled Release 
In vitro controlled release was performed using a dialysis method. Specifically, a known 
amount of solid nanoparticles (6 mg), containing a TQ amount established by the method 
described above, were re-suspended in phosphate buffer (2mL of 0.1M Na2HPO4-NaH2PO4, pH 
7.4). This suspension was placed in a dialysis bag (Specta/Por, MWCO 1000Da, Spectrum 
Laboratories, Rancho-Dominguez, CA, USA) that was further placed in the phosphate buffer 
release medium (15 mL) and incubated at 37 ºC in a refrigerated orbital shaker (CO24, Edison, 
NJ, USA). Various time intervals were investigated. At each time point, the release medium was 
completely replaced with fresh release medium, and placed back in the shaker chamber for 
further TQ release. The sink conditions calculated based on TQ solubility, TQ amount contained 
in the nanoparticles, and the total volume of release medium, were maintained throughout the 
experimental time. The percentage (%) release for every time point was calculated as percentage 
of total entrapped drug. Following the same procedure, a control experiment was performed 
using TQ suspension in phosphate buffer. 
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3.2.8 Antioxidant Activity of TQ-loaded Nanoparticles 
The antioxidant activity of TQ-loaded nanoparticles was determined by use of 2,2-
diphenyl-1-picrylhydrazyl (DPPH) assay. 
21, 40
 Briefly, in a 96-well plate, 100 µL of 100 µM 
DPPH solution in methanol was incubated with 100 µL of aqueous suspensions of TQ-loaded 
nanoparticles prepared with different molecular micelles as well as solutions of TQ dissolved in 
methanol. Methanol and empty nanoparticles (synthesized without TQ) were also incubated with 
DPPH solution, and used as controls. After 30 minutes, the absorbance was read at 517 nm using 
a microplate spectrophotometer (Model 680, Bio-Rad Laboratories, Hercules, CA, USA). The 
scavenging activity for each sample was calculated as DPPH scavenging (%) = 100 x [(Acontrol-
Asample)/Acontrol], where Asample is the absorbance of DPPH in the presence of TQ-containing 
samples, and Acontrol is the absorbance of DPPH for control samples in the absence of TQ. The 
concentration of TQ in each nanoparticle sample and in free TQ solution for which 50% DPPH 
scavenging is achieved (IC50), was used to compare the scavenging activity. In addition, Trolox, 
a powerful water soluble antioxidant, was used as standard in the DPPH assay. Trolox 
Equivalents were calculated as the ratio between the IC50 for Trolox and the IC50 for each 
sample, and expressed as µmol Trolox/ g TQ. All experiments were performed in triplicate. 
3.2.9 Cytotoxicity of TQ-loaded Nanoparticles 
 The cytotoxic effect of TQ and TQ-loaded nanoparticles on breast normal and cancer cell 
lines was determined by use of CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay 
(Promega Corporation, Madison, Wisconsin, USA). Normal breast (Hs578Bct) and breast cancer 
(hormone-dependent MCF-7 and hormone independent MDA-MB-231) cell cultures (1x10
4
 
cells/well, 50 µL) were incubated at 37 ºC, in 5% CO2,  with TQ solutions containing less than 
1% DMSO, and TQ-loaded nanoparticles (3 mg/mL) suspended in the culture media (50 µL) for 
24, 48 and 72 hours. At the end of the incubation period, the cells were treated with 3-(4,5-di- 
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methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium salt (MTS) 
(20 µL), according to the manufacturer’s instructions (CellTiter 96
®
 AQueous One Solution Cell 
Proliferation Assay, Promega, Madison, WI). After 1 hour, the absorbance was read at 490 nm 
using a microplate spectrophotometer (Benchmark Plus, Bio-Rad Laboratories, Hercules, CA, 
USA). Blank nanoparticles prepared by emulsification solvent evaporation, without adding TQ 
to the formulation, were used as controls. Percentage cell viability was calculated as 100 times 
the ratio of absorbance in the presence of TQ and TQ-loaded nanoparticles and absorbance for 
TQ-free control samples. All experiments were performed in triplicate. 
3.3. Results and Discussion 
3.3.1 Nanoparticle Characterization 
TQ-loaded PLGA nanoparticles were synthesized by emulsification evaporation using 
molecular micelles as emulsifiers. In our previous studies, molecular micelles demonstrated 
excellent emulsifying properties offering uniform and nanometer size nanoparticles. In addition, 
nanoparticle high surface charge conferred by molecular micelles allowed enhanced stability in 
aqueous solution.
51
 The physico-chemical properties of TQ-loaded nanoparticles prepared with 
molecular micelles as emulsifiers are presented in Table 3.1.  TQ-loaded PLGA nanoparticle 
sizes ranged from 123.5 to 187.4 nm, depending on the micelle structure. The particle sizes for 
nanoparticles emulsified with poly-SHG and poly-SUV were significantly higher (p-value = 
0.05) than the other nanoparticles. It should be mentioned that micelles with short carbon chain 
(C7) such as poly-SHG were likely more flexible and less hydrophobic than micelles containing 
longer carbon chains (C11) such as poly-SUG. Therefore, their interactions with PLGA were 
likely reduced leading to an increase in particle size. In addition, micelles having larger 
hydrophilic head groups such as poly-SUV likely preferred in the aqueous phase as compared to 
organic phase. Such interactions likely lead to an increase in particle size as well. For closely 
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related molecular micelles such as poly-SDG, poly-SUG, and poly-SUA, the particle size 
remained approximately the same. In contrast, polydispersity indicated by polydispersity index 
(PDI) remained constant and below 0.100, indicating monodisperse nanoparticle suspensions for 
all micelles. In addition, molecular micelles conferred high negative charge on the nanoparticle 
surface as indicated by the values of zeta potential. Statistical analysis revealed that both the PDI 
and zeta potential remained unchanged (p-value = 0.05) regardless of the investigated emulsifier. 
 
Table 3.1  Physico-chemical properties of TQ-loaded PLGA nanoparticles (n=4) 
Emulsifier Size PDI 
Zeta potential 
(mV) 
Poly-SHG 177.7 ± 9.7 0.054 ± 0.010 -60.8 ± 2.6 
Poly-SDG 146.5 ± 19.5 0.083 ± 0.024 -59.1 ± 4.8 
Poly-SUG 164.1 ± 15.5 0.083 ± 0.003 -60.0 ± 5.2 
Poly-SUA 149.3 ± 9.5 0.071 ± 0.012 -60.7 ± 3.1 
Poly-SUL 144.8 ± 21.3 0.061 ± 0.011 -62.4 ± 1.9 
Poly-SUV 173.1 ± 8.8 0.091 ± 0.070 -60.9 ± 8.0 
Note: Other conditions were PLGA (100 mg); TQ (15 mg), and  
          emulsifier (0.5% w/v). 
 
Furthermore, TQ-loaded PLGA nanoparticles presented uniform well-defined spherical 
shape as shown in Figure 3.3. Our results indicated that all molecular micelles used in this study 
provided excellent emulsifier properties, leading to small monodisperse particle size, highly 
negative surface charge, and uniform spherical shapes. 
3.3.2 Optimization of TQ Entrapment Efficiency 
The entrapment efficiency of TQ-loaded nanoparticles was investigated using a Box-
Behnken optimization design. Compared with other designs, Box-Behnken design presents 
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several advantages such as pre-established limits of design variables, and a reduced number of 
experiments 
58
. The experimental design involved fifteen experiments including three central 
level experiments for reproducibility purposes. The design allowed an investigation of the 
simultaneous effects of PLGA amount (mg), TQ amount (mg), and poly-SUG concentration (% 
w/v) (design variables) on the entrapment efficiency (response). The limits of design variable 
ranges were selected based on preliminary experiments that indicated that TQ is more 
compatible with high molecular weight polymers than low molecular weight polymers. In 
addition, we found that drug precipitation occurred at a drug loading higher than 25 mg. 
therefore, in our further experiments, high molecular weight PLGA polymer (MW 66-107 kDa) 
and a drug loading less than 25 mg were used. 
 
 
Figure 3.3 Transmission electron micrograph of TQ-loaded PLGA nanoparticles 
(magnification 33,000x) prepared with poly-SHG. 
 
In addition, poly-SUG was selected as emulsifier for optimization due to its high 
availability, and easy synthesis. Detailed experimental conditions are presented in Table 3.2. For 
all experiments included in the Box-Behnken optimization design, the particle size of TQ-loaded 
PLGA nanoparticles containing various amounts of TQ varied between approximately 123 and 
167 nm, likely due to various amounts of poly-SUG used in each formulation.  Monodisperse 
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nanoparticle suspensions were obtained for all fifteen experiments used in the design, as shown 
by a polydispersity index (PDI) lower than 0.100. 
 
Table 3.2 Experimental conditions used in Box-Behnken experimental design 
Exp. No. PLGA (mg) TQ (mg) 
Poly-SUG 
(%w/v) 
EE % Size PDI 
1 50 25 0.75 10.8 158.0 0.063 
2 75 15 0.75 21.9 164.9 0.054 
3 75 5 0.5 28.4 167.4 0.071 
4 50 5 0.75 10.5 123.4 0.070 
5 75 15 0.75 27.3 162.8 0.064 
6 50 15 0.5 21.3 141.5 0.050 
7 100 15 0.5 35.1 157.0 0.059 
8 75 25 0.5 20.9 130.2 0.049 
9 100 5 0.75 26.7 142.8 0.062 
10 50 15 1 10.5 127.3 0.073 
11 75 15 0.75 24.3 129.8 0.050 
12 100 25 0.75 25.6 143.6 0.051 
13 75 5 1 32.7 127.6 0.047 
14 100 15 1 29.8 132.7 0.047 
15 75 25 1 22.3 125.2 0.068 
 
The investigated variables strongly influenced the entrapment efficiency as indicated by 
the response surface represented in Figure 3.4. When the entrapment efficiency was represented 
as a function of PLGA amount and TQ amount (Figure 3.4.A), the highest entrapment efficiency 
range was obtained for increased amounts of PLGA (above 80 mg) and TQ amounts lower than 
20 mg, possibly due to increased viscosity of the organic phase that would retain greater amounts 
of TQ. The effect of emulsifier on the entrapment efficiency is shown in Figure 3.4.B.  
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A) 
 
 
B) 
 
Figure 3.4 Response surface for entrapment efficiency represented as a function of A) TQ 
(mg) and PLGA (mg); and B) TQ (mg) and poly-SUG (% w/v). The highest 
entrapment efficiency is shown by the red zones. 
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The entrapment efficiency increased with the decrease of poly-SUG concentration. The 
highest entrapment efficiency was obtained for poly-SUG concentrations lower than 0.55 % w/v. 
Larger values of entrapment efficiency were obtained for a poly-SUG concentrations higher than 
0.55 % w/v as well. It should be noted that molecular micelles have the ability to incorporate 
hydrophobic compounds 
56, 59-61
 In molecular micelle-assisted nanoparticle synthesis, a biphasic 
system containing a micellar aqueous solution and an organic polymeric phase was involved. 
Therefore, the partition of the drug between the two phases likely affected the drug entrapment 
into the polymeric matrix.  
When molecular micelles are present at the aqueous-organic interface in order to stabilize 
the emulsion, they would likely incorporate a portion of the TQ. Such TQ portion was eliminated 
in the precipitation and purification steps by centrifugation. In addition, the TQ phase partition 
can be changed towards organic phase by decreasing the molecular micelle concentration. 
However, the decrease is limited by the minimum micelle concentration necessary for synthesis 
of stable, and uniform particle sizes. Therefore, we found that the maximum entrapment 
efficiency was obtained for 100 mg PLGA, 15 mg TQ and 0.5 % w/v poly-SUG, and these 
conditions were considered as optimum for further experiments. 
Multivariate regression was used to correlate the investigated design variables with the 
entrapment efficiency. A quadratic model was constructed based on experimental data and is 
described by equation 3.1: 
 
EE%  = b0+b1[PLGA]+b2[TQ]+b3[MM]+b4[PLGA]
2
+b5[TQ]
2
+b6[MM]
2
                             3.1 
 
where EE% is the entrapment efficiency, described above; [PLGA] is the amount of PLGA (mg); 
[TQ] is the amount of TQ (mg); [MM] is the emulsifier concentration (% w/v); b0 is the 
intercept; and b1- b6 are the correlation coefficients for each of the equation terms.  
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Analysis of variance (ANOVA) was further used to establish the significance of design 
variables and their interactions with the response. The results of analysis of variance of the 
regression model are presented in Table 3.3. The design variables were considered significant for 
a p-value lower than 0.05. ANOVA results indicated that the most significant variable 
influencing the entrapment efficiency is the PLGA amount (p-value 0.0004), followed by TQ 
amount and molecular micelle concentration. 
 
Table 3.3 Analysis of variance for Box-Behnken model 
Variables p-value b-coefficients 
Intercept 0.2653 b0 7.905 
[PLGA] 0.0004 b1 0.32 
[TQ] 0.1278 b2 -0.234 
[MM] 0.3731 b3 -5.203 
[PLGA]
2
 0.0823 b4 -2.303 
[TQ]
2
 0.3335 b5 -1.194 
[MM]
2
 0.1053 b6 2.118 
 
In addition, validation of the regression model was achieved by comparing the predicted 
response with the response values of the central samples of the design as well as independent 
optimum experiments separated from the experimental design. The predicted and the 
experimental entrapment efficiencies as well as the levels of the investigated variables are 
presented in Table 3.4. It can be noted that the predicted and measured values were identical for 
central samples presenting a percent relative error of 0.00 % and good predictive ability of the 
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model. In case of experiments performed at the optimum conditions, the percent relative error 
was 2.39 % suggesting high predictability of the model. 
 
Table 3.4 Predictability of Box-Behnken model 
Experiments 
PLGA  
(mg) 
TQ  
(mg) 
Poly-SUG  
(%w/v) 
Predicted 
EE% 
Measured 
EE% 
% RE 
Central  75 15 0.75 24.49 24.49 0.00 
Optimum 100 15 0.5 33.46 34.26 2.39 
Note:    Percent relative error (% RE) = 100*(Predicted EE – Measured EE)/Predicted EE;              
             EE = entrapment efficiency 
 
3.3.3 The Effect of Molecular Micelles on the Entrapment Efficiency 
In order to evaluate the effect of the molecular micelles on entrapment efficiency of TQ-
loaded PLGA nanoparticles, the short chain molecular micelles poly-SHG and poly-SDG as well 
as micelles having various amino acid head group such as poly-SUA, poly-SUL, and poly-SUV 
were used as emulsifiers. The nanoparticles were synthesized using optimum conditions as 
determined using Box-Behnken design: 100 mg PLGA, 15 mg TQ, and 0.5 % w/v emulsifier, 
respectively. The values of TQ entrapment efficiency for TQ-loaded PLGA nanoparticles 
prepared with various micelles are presented in Table 3.5. The values of entrapment efficiency 
were similar for all molecular micelles, regardless of their structure, indicating that the type of 
the micelle was not a significant factor in the Box Behnken optimization design. 
3.3.4 Release Profile of Optimized TQ-loaded PLGA Nanoparticles  
TQ-loaded PLGA nanoparticles were synthesized at the optimum conditions using 
various molecular micelles as emulsifiers. The TQ release from these nanoparticles was 
investigated for a period of 72 hours.   
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Table 3.5  Effect of emulsifier on entrapment efficiency of TQ-loaded PLGA nanoparticles 
(n=4) 
 
 
Emulsifier Poly-SHG Poly-SDG Poly-SUG Poly-SUA Poly-SUL Poly-SUV 
EE% 
32.09 ± 
2.85 
34.63 ± 
2.96 
34.26 ± 
1.08 
33.69 ± 
4.72 
35.17 ± 
4.90 
37.20 ± 
8.65 
 
The release occurred based on the diffusion of TQ from the TQ-loaded nanoparticles 
placed in a dialysis bag to an external aqueous phase. The release profiles for the first 8 hours are 
shown in Figure 3.5. It was observed that the TQ release levels were strongly influenced by the 
emulsifier used in the nanoparticle synthesis. TQ-loaded nanoparticles had a release of 30-60% 
for the first hour depending on the emulsifier while a control sample containing equivalent TQ 
showed a release level of 80% within the same period of time. However, all nanoparticle 
formulations showed a rapid release in the first 8 hours with similar release rates followed by a 
plateau at different release levels. It is possible that TQ was not uniformly distributed in the 
nanoparticle matrix, a portion being situated near the surface of the nanoparticles rather than 
inside, and therefore leading to a rapid release in the first hours.  
The nanoparticles prepared with poly-SHG and poly-SUG showed a similar release of 
approximately 75% of the drug for the same period of time (8 hours). Thus, a shorter carbon 
chain of the molecular micelles did not change the release profile. The lowest released amount 
was given by the nanoparticles prepared with poly-SUA. Varying the amino acid head group of 
the micelles from alanine to valine resulted in higher release level for poly-SUV-emulsified 
nanoparticles as compared to poly-SUA. In addition, it is possible that molecular micelles with 
longer carbon chains adhered stronger to the nanoparticle surface as compared with shorter 
carbon chains. Furthermore, the interface micelle layer could be of a different density in case of 
poly-SUA as compared with poly-SUG likely determining a slower release.  
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After eight hours, there was no significant release observed, and the amount of released 
drug remained approximately constant until 72 hours (the total investigated time). 
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8
hours
C
u
m
u
la
ti
v
e
 r
e
le
a
s
e
 (
%
)
TQ
poly-SUG
poly-SHG
poly-SDG
poly-SUV
poly-SUL
poly-SUA
  
Figure 3.5 Release profile of TQ-loaded nanoparticles prepared with various molecular 
micelles. 
 
3.3.5 Antioxidant Activity of Optimized TQ-loaded PLGA Nanoparticles 
 The antioxidant activities of TQ and TQ-loaded PLGA nanoparticles synthesized at the 
optimum conditions were evaluated by use of the DPPH scavenging assay. The concentration of 
TQ (mg/mL) for which 50% inhibition was reached was expressed as IC50 (mg TQ/mL). In 
general, a high scavenging activity is indicated by a small IC50. The DPPH scavenging activities 
of TQ and TQ-loaded PLGA nanoparticles are presented in Table 3.6. The IC50 for the free drug 
was 0.132 ± 0.003 mg/mL while the TQ-loaded PLGA nanoparticles presented a smaller IC50. 
For example, the IC50 for TQ-loaded nanoparticles emulsified with poly-SUA was 0.023 ± 
0.001 mg/mL, representing an improved antioxidant activity. A lower antioxidant activity of 
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nanoparticles was obtained for poly-SHG (IC50 = 0.107 ± 0.020 mg/mL), but comparable with 
the one of free TQ.  
In addition, Trolox Equivalents were calculated based on the ratio between IC 50 of 
Trolox and the IC50 of each sample. A high Trolox Equivalents number indicates a high 
antioxidant activity as compared to a powerful antioxidant such as Trolox. Similarly, Trolox 
Equivalents were the highest for poly-SUA (753.73 ± 18.39 µmol Trolox/g TQ), closely 
followed by poly-SUV–emulsified nanoparticles (597.48 ± 42.96 µmol Trolox/g TQ).  
 
Table 3.6 DPPH scavenging activity of TQ and TQ-loaded PLGA nanoparticles (n=3) 
Sample 
IC50 
(mg/mLTQ) 
Trolox Equivalents 
(µmol Trolox/g TQ) 
TQ 0.132 ± 0.003 132.25 ± 4.22 
Poly-SHG 0.107 ± 0.020 168.56 ± 29.91 
Poly-SDG 0.044 ± 0.004 404.36 ± 32.99 
Poly-SUG 0.052 ± 0.002 341.65 ± 14.07 
Poly-SUA 0.023 ± 0.001 753.73 ± 18.39 
Poly-SUL 0.036 ± 0.005 494.74 ± 69.38 
Poly-SUV 0.030 ± 0.002 597.48 ± 42.96 
 
In addition, we observed that the DPPH scavenging activity inversely correlated with the 
release profile of TQ-loaded nanoparticles, as the slowest release of poly-SUA–emulsified 
nanoparticles had shown the highest antioxidant activity. It should be mentioned that DPPH 
radical is not soluble in water, and likely can diffuse into a more hydrophobic environment 
offered by nanoparticles. Therefore, assuming that the reaction with DPPH radicals can take 
place inside the PLGA nanoparticles, it is possible that the TQ present in the PLGA nanoparticle 
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environment had better solubility in case of poly-SUA as compared to other micelles. However, 
all TQ-loaded nanoparticles showed improved DPPH scavenging activity as compared with free 
TQ indicating that such nanoparticle systems could be excellent candidates as free radical 
scavengers. 
3.3.6 Cytotoxicity of TQ and Optimized TQ-loaded PLGA Nanoparticles 
 In general, cell viability refers to the number of cells that remain viable after the 
treatment with a drug or drug delivery system. Cytotoxicity is the property of a drug that induces 
cell death, preferably in cancer cells for anticancer drugs. Cytotoxic properties of drugs and drug 
delivery systems are typically measured by cell viability assays. In this study, MTS assay was 
used to evaluate the cell viabilities of TQ and optimized TQ-loaded PLGA nanoparticles for 
normal breast cells (Hs578Bct), and cancer breast cells (MCF-7 and MDA-MB-231) at 24, 48 
and 72 hours. In cytotoxicity studies of polymeric nanoparticles, several important aspects 
should be taken into consideration. First, the components of nanoparticles, including the 
polymer, the drug, and the emulsifier should not present any toxicity against both normal and 
cancer cells. Second, the desired effect for cancer cells is typically to obtain low cell viability 
within a short period of time, using drug concentrations that should not significantly affect the 
viability of normal cells.  
Cell viability results for normal breast (Hs578Bct), and cancer breast cells (MCF-7 and 
MDA-MB-231) in the presence of TQ are presented in Figure 3.6. It can be noticed that a low 
concentration of free TQ (50 µM) did not affect cell viability of both normal and cancer cells 
irrespective of incubation time (24, 48 and 72 hours). However, at an increased concentration of 
TQ (200 µM), the cell viability critically decreased to 12.03 ± 0.67 % for normal cells in the first 
24 hours, and remained fairly constant afterwards (48 and 72 hours). This like suggests that  such 
high TQ concentration was toxic to the cells. 
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Figure 3.6 Cell viability of A) Hs578Bct normal breast cells; B) MCF-7 breast cancer cells; 
and C) MDA-MB-231 breast cancer cells incubated with TQ. 
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In the case of cancer cells, low concentrations of TQ (50 and 100 µM) did not have a 
significant reduction in the cell viability for both MCF-7 and MDA-MB-231 cancer cells within 
the investigated period of time (72 hours). However, when the TQ concentration increased to 
200µM, the MCF-7 cell viability decreased to 27.29 ± 6.52 % after 24 hours, and slightly 
increased to 37.42 ± 4.83 % after 72 hours. With regard to MDA-MB-231 cancer cells, the 
viability decreased progressively in time to 45.5 ± 8.58 % after 72 hours for 200 µM TQ 
indicating that such cells are more resistant to TQ treatment than MCF-7 cells. Although a high 
dosage of TQ (200 µM) was useful for breast cancer inhibition, it was toxic to normal cells. Such 
effects were not desirable because at this concentration the toxicity of TQ was higher for normal 
cells than for cancer cells. 
Optimized TQ-loaded PLGA nanoparticles as well as blank nanoparticles prepared 
without TQ and (containing an average of 279.1 ± 47.7 µM TQ) were also incubated with normal 
breast cells (Hs578Bct) and cancer breast cells (MCF-7 and MDA-MB-231). The cell viabilities 
of normal cells in the presence of blank and TQ-loaded nanoparticles are presented in Figure 3.7. 
The lowest cell viabilities were obtained for poly-SUL - emulsified blank nanoparticles (71.52 ± 
2.11 %), followed closely by poly-SUA - emulsified blank nanoparticles (72.14 ± 4.61 %) at 72 
hours. It can be noted that cell viability remained above 90 % for all blank nanoparticles 
emulsified with the other molecular micelles used in this study, irrespective of emulsifier. This 
indicates that the polymer and the emulsifier had no cytotoxic effect on normal cells. In the case 
of TQ – loaded nanoparticles incubated with normal cells, the cell viability decreased 
progressively in time from ~ 80 – 100 % after 24 hours to ~ 40 – 80% after 48 hours. After 72 
hours, the lowest cell viability was obtained for poly-SDG–emulsified nanoparticles (30.95 ± 
7.48 %) and poly-SUL–emulsified nanoparticles (37.05 ± 13.29 %). This effect was not observed 
for empty nanoparticles emulsified with the same molecular micelles.  
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Figure 3.7 Cell viability of Hs578Bct normal breast cells in the presence of blank and TQ- 
  loaded nanoparticles. 
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Therefore, the decrease in the cell viability was likely due to nanoparticle cell uptake and 
TQ release in the cellular media. In contrast, poly-SUV emulsified TQ-loaded nanoparticles 
provided the highest cell viability (85.79 ± 7.04 %) after 72 hours having the desired effect of 
low toxicity for normal cells.  
The results for cell viability of MCF-7 and MDA-MB-231 cancer cells incubated with 
TQ-loaded nanoparticles are presented in Figure 3.8. For these nanoparticles, we did not observe 
a significant decrease in the cell viability after 24 and 48 hours for any of the nanoparticles. Such 
effect can be determined by insufficient cellular uptake and metabolism of the cells after the 
incubation with nanoparticles. We observed an overgrowth of both cancer cell lines incubated 
with TQ-loaded poly-SDG–emulsified nanoparticles. Similar effect was observed in case of 
blank poly-SDG–emulsified nanoparticles incubated with the cancer cells, indicating that such 
effect is likely induced by the emulsifier and not by the entrapped TQ. The MCF-7 cell viability 
decreased for all TQ-loaded nanoparticles at 72 hours.  The lowest cell viability was obtained for 
poly-SUL–emulsified nanoparticles (43.26 ± 9.45 %), which is comparable with that obtained 
for equivalent free TQ (37.42 ± 4.83 %).  For MDA-MB-231 breast cancer cells incubated with 
poly-SUL–emulsified nanoparticles, the cell viability was slightly higher (59.16 ± 4.52 %) than 
for MCF-7 cells, likely due to the drug-resistance of such cells. However, it should be noted that 
TQ-loaded nanoparticles emulsified with poly-SUV reached a cell viability of 68.47 ± 8.42 % for 
MDA-MB-231 cells, while the cell viability was higher for normal cells (85.79 ± 7.04 %) treated 
with the same nanoparticles. Although TQ-loaded nanoparticles emulsified with poly-SUV did 
not affect the cell viability of MCF-7 cells, their performance was improved for MDA-MB-231 
cells. Considering that free TQ generated a low cell viability for both normal and cancer cells, 
TQ-loaded nanoparticles emulsified with poly-SUV can be potentially used as drug delivery 
systems  for breast cancer inhibition. 
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Figure 3.8 Cell viability of MCF-7 cancer cells (left); and MDA-MB-231 cancer cells (right) 
incubated with blank PLGA nanoparticles and TQ-loaded PLGA nanoparticles 
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optimum synthetic conditions such as PLGA amount, TQ amount, and emulsifier concentration 
were obtained for maximum entrapment efficiency. 
The molecular micelles strongly influenced the TQ release profile, the antioxidant and 
cytotoxic properties of TQ-loaded PLGA nanoparticles. Molecular micelles offered high 
flexibility to nanoparticle physico-chemical and biological properties and, therefore, can be used 
in the synthesis of drug-loaded nanoparticles depending on the desired properties. In addition, 
such nanoparticles are promising as free radical scavengers and inhibitors of breast cancer cells. 
3.5. References 
1 Dalle-Donne, I.; Rossi, R.; Colombo, R.; Giustarini, D.; Milzani, A. Clinical Chemistry 
2006, 52, 601-623. 
2 Molavi, B.; Mehta Jawahar, L. Current Opinion in Cardiology 2004, 19, 488-493. 
3 Passi, S.; Gianni, G.; Cocchi, M. Progress in Nutrition 2006, 8, 241-256. 
4 Manea, A.; Constantinescu, E.; Popov, D.; Raicu, M. Journal of Cellular and Molecular 
Medicine 2004, 8, 117-126. 
5 Goetz, M. E.; Luch, A. Cancer Letters 2008, 266, 73-83. 
6 Afonso, V.; Champy, R.; Mitrovic, D.; Collin, P.; Lomri, A. Joint, Bone, Spine 2007, 74, 
324-329. 
7 Sorg, O. Comptes Rendus Biologies 2004, 327, 649-662. 
8 Kohen, R.; Nyska, A. Toxicologic Pathology 2002, 30, 620-650. 
9 Pokorny, J.; Yanishlieva, N.; Gordon, M. Antioxidants in food 2001, CRC Press LLC, 
Boca Raton, Forida, 87-249. 
10 Bland, J. S. Alternative Therapies 1996, 2, 73-76. 
11 Zhou, B.; Liu, Z.-L. Pure Applied Chemistry 2005, 77, 1887-1903. 
12 Borek, C. Integrative Cancer Therapies 2004, 3, 333-341. 
13 Garewal, H. S. Antioxidants and disease prevention 1997, CRC Press LLC, Boca Raton, 
Florida, 3-177. 
14 Milbury, P. E.; Richer, A. C. Understanding the antioxidant controversy: scrutinizing the 
"fountain of youth" 2008, Praeger Publishers, Westport, Connecticut, 1-14. 
 100 
15 Parada, J.; J.M., A. Journal of Food Science 2007, 7, R21-R32. 
16 Shoji, Y.; Nakashima, H. Journal of Drug Targeting 2004, 12, 385-391. 
17 Kaur, I. P.; Kapila, M.; Agrawal, R. Ageing Research Reviews 2007, 6, 271-288. 
18 Dziubla, T.; Muro, S.; Muzykantov, V. R.; Koval, M. Oxidative Stress, Disease and 
Cancer 2006, 1023-1043. 
19 Sheu, S. S.; Nauduri, D.; Anders, M. W. Biochimica Et Biophysica Acta-Molecular Basis 
of Disease 2006, 1762, 256-265. 
20 Ratnam, D. V.; Ankola, D. D.; Bhardwaj, V.; Sahana, D. K.; Kumar, M. Journal of 
Controlled Release 2006, 113, 189-207. 
21 Wu, T. H.; Yen, F. L.; Lin, L. T.; Tsai, T. R.; Lin, C. C.; Cham, T. M. International 
Journal of Pharmaceutics 2008, 346, 160-168. 
22 Zhang, Y.; Yang, Y.; Tang, K.; Hu, X.; Zou, G. Journal of Applied Polymer Science 
2008, 107, 891-897. 
23 Bala, I.; Bhardwaj, V.; Hariharan, S.; Sitterberg, J.; Bakowsky, U.; Kumar, M. 
Nanotechnology 2005, 16, 2819-2822. 
24 Bala, I.; Bhardwaj, V.; Hariharan, S.; Kharade, S. V.; Roy, N.; Kumar, M. N. V. R. 
Journal of Drug Targeting 2006, 14, 27-34. 
25 Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Journal of 
Nanobiotechnology 2007, 5:3, 1-18. 
26 Kurzrock, R.; Li, L.; Mehta, K.; Aggarwai, B. B.; Liposomal curcumin for treatment of 
cancer: WO/2004/080396, 2004, pp 66. 
27 Trumpower, B. L. Journal of Bioenergetics and Biomembranes 1981, 13, 1-24. 
28 Gutierrez, P. L. Frontiers in Bioscience 2000, 5, 629-638. 
29 Horvath, R.; Gorman, G.; Chinnery, P. F. Neurotherapeutics 2008, 5, 558-568. 
30 Quinzii, C. M.; Lopez, L. C.; Naini, A.; DiMauro, S.; Hirano, A. Biofactors 2008, 32, 
113-118. 
31 Ankola, D. D.; Viswanad, B.; Bhardwaj, V.; Ramarao, P.; Ravi Kumar, M. N. V. 
European Journal of Pharmaceutics and Biopharmaceutics 2007, 67, 361-369. 
32 Hsu, C.-H., Coenzyme Q10 nanoparticles engineered from microemulsion precursors for 
oral delivery, 2004. 
33 Nehilla, B. J.; Bergkvist, M.; Popat, K. C.; Desai, T. A. International Journal of 
Pharmaceutics 2008, 348, 107-114. 
 101 
34 Alcain, F. J.; Villalba, J. M. Expert Opinion on Therapeutic Patents 2007, 17, 649-665. 
35 Neckers, L.; Neckers, K. Expert Opin Emerg Drugs 2005, 10, 137-149. 
36 Dettrakul, S.; Surerum, S.; Rajviroongit, S.; Kittakoop, P. Journal of Natural Products 
2009, 72, 861-865. 
37 Muhammad, I.; Takamatsu, S.; Walker, L. A.; Mossa, J. S.; Fong, H. H. S.; El-Feraly, F. 
S. Phytotherapy Research 2003, 17, 887-891. 
38 Snader, K. M. Anticancer agents from natural products 2005, CRC Press Boca Raton, 
Florida, 339-356. 
39 Salem, M. L. International Immunopharmacology 2005, 5, 1749-1770. 
40 Badary, O. A.; Taha, R. A.; El-Din, A. M. G.; Abdel-Wahab, M. H. Drug and Chemical 
Toxicology 2003, 26, 87-98. 
41 Burits, M.; Bucar, F. Phytotherapy Research 2000, 14, 323-328. 
42 Badary, O. A.; Abdel-Naim, A. B.; Adel-Wahab, M. H.; Hamada, F. M. A. Toxicology 
2000, 143, 219-226. 
43 Nagi, M. N.; Mansour, M. A. Pharmacological Research 2000, 41, 283-289. 
44 Gali-Muhtasib, H.; Roessner, A.; Schneider-Stock, R. International Journal of 
Biochemistry & Cell Biology 2006, 38, 1249-1253. 
45 Shoieb, A. M.; Elgayyar, M.; Dudrick, P. S.; Bell, J. L.; Tithof, P. K. International 
Journal of Oncology 2003, 22, 107-113. 
46 Gali-Muhtasib, H.; Diab-Assaf, M.; Boltze, C.; Al-Hmaira, J.; Hartig, R.; Roessner, A.; 
Schneider-Stock, R. International Journal of Oncology 2004, 25, 857-866. 
47 Scifinder Scifinder Scholar, Advanced Chemistry Development (ACD/Labs) software, 
V8.14 for Solaris 2007, accessed September 2007. 
48 Badary, O. A.; Al-Shabanah, O. A.; Nagi, M. N.; Al-Bekairi, A. M.; Elmazar, M. M. A. 
Drug Development Research 1998, 44, 56-61. 
49 Ali, B. H.; Blunden, G. Phytotherapy Research 2003, 17, 299-305. 
50 Esmaeili, F.; Ghahremani, M. H.; Esmaeili, B.; Khoshayand, M. R.; Atyabi, F.; 
Dinarvand, R. International Journal of Pharmaceutics 2008, 349, 249-255. 
51 Ganea, G. M.; Sabliov, C. M.; Ishola, A. O.; Fakayode, S. O.; Warner, I. M. Journal of 
Nanoscience and Nanotechnology 2008, 8, 280-292. 
52 Zhao, Y. F.; Sugiyama, S.; Miller, T.; Miao, X. G. Expert Review of Medical Devices 
2008, 5, 395-405. 
 102 
53 Macossay, J.; Shamsi, S. A.; Warner, I. M. Tetrahedron Letters 1999, 40, 577-580. 
54 Akbay, C.; Gill, N. L.; Powe, A.; Warner, I. M. Electrophoresis 2005, 26, 415-425. 
55 Billiot, F. H.; Billiot, E. J.; Warner, I. M. Journal of Chromatography A 2001, 922, 329-
338. 
56 Thibodeaux, S. J.; Billiot, E.; Warner, I. M. Journal of Chromatography A 2002, 966, 
179-186. 
57 Akbay, C.; Gill, N. L.; Agbaria, R. A.; Warner, I. M. Electrophoresis 2003, 24, 4209-
4220. 
58 Govender, S.; Pillay, V.; Chetty, D. J.; Essack, S. Y.; Dangor, C. M.; Govender, T. 
International Journal of Pharmaceutics 2005, 306, 24-40. 
59 Akbay, C.; Gill, N. L.; Warner, I. M. Electrophoresis 2007, 28, 1752-1761. 
60 Shamsi, S. A.; Palmer, C. P.; Warner, I. M. Analytical Chemistry 2001, 73, 140A-149A. 
61 Valle, B. C.; Morris, K. F.; Fletcher, K. A.; Fernand, V.; Sword, D. M.; Eldridge, S.; 
Larive, C. K.; Warner, I. M. Langmuir 2007, 23, 425-435. 
 
 
 103 
CHAPTER 4 
FLUORESCENT RATIOMETRIC MOLECULAR MICELLE - MODIFIED  
POLY(D,L LACTIDE-CO-GLYCOLIDE) NANOPARTICLES  
FOR DETECTION OF HYDROXYL RADICALS 
 
4.1 Introduction 
Aerobic organisms produce the energy necessary for their life by oxidation of biological 
substrates in the presence of oxygen. Complete oxygen reduction takes place in mitochondria 
involving a series of redox reactions controlled by a complex enzymatic mechanism. Such 
reactions generate radical and non-radical reactive oxygen species, i.e. superoxide anion
 
(O2
•-
), 
hydroxyl radical (OH
•
), singlet oxygen
 
(
1
O2), and hydrogen peroxide (H2O2). The cells are 
exposed to oxidative stress when an unbalance exists between the free radical production of their 
elimination by various reducing agents, enzymes, and other antioxidants.
1-3
 Reactive oxygen 
species are involved in many metabolic processes, including signal transduction, carcinogenesis, 
and inflammatory response. In addition, excessive production of radical species can lead to 
alteration of cellular functions responsible for cardiovascular diseases, neurodegenerative 
diseases, diabetes, cancer, joint diseases, and aging.
4-9
  
In the cellular oxidation process, hydroxyl radical can be produced by Fenton and 
Habber-Weiss reactions of hydrogen peroxide with transition metals such as iron and copper.
2, 8
 
Hydroxyl radical has a short half-life, and is considered the most aggressive free radical, mainly 
due to its high reactivity. It is able to react with lipids, amino acids, proteins, DNA, and sugars at 
extremely high rates, leading to cell damage and even cell death.
10
 Other exogenous sources such 
as ozone and ionization radiation lead to hydroxyl radical generation as well.  
Reactive oxygen species can be detected by a variety of methods, including electron spin 
resonance (ESR), UV-Vis, fluorescence, and luminescence spectroscopy.
11
 Compared to the 
other methods, fluorescence sensors provide several advantages such as high specificity, 
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localized information at the target site, versatility of detection scheme, including fluorescence 
spectroscopy and fluorescence microscopy for both in vitro and in vivo detection.
12-14
 In 
particular, coumarin 3-carboxylic acid (C3C) has been used as a fluorescent sensor for detection 
of hydroxyl radical.
15
 The non-fluorescent C3C molecule reacts with hydroxyl radical and 
undergoes hydroxylation at position C7 of the coumarin structure, producing a highly fluorescent 
compound, 7-hydroxy coumarin 3-carboxylic acid (7-OH C3C) with the emission at 450 nm 
when excited in the 400-410 nm region.
15-17
 In the chemical structure of C3C, the carboxylic 
group in the C3 position can be easily coupled with other molecules via a peptide bond. 
Therefore, other coumarin derivatives such as the succinimidyl ester of C3C (SECCA), 
phospholipid - linked coumarins, and C3C – derivatized amino acids and peptides were used for 
the detection of hydroxyl radicals.
18-20
 
Although fluorescent probes have been successfully used to detect hydroxyl radicals, 
several limitations should be taken into consideration. For example, the changes in the 
fluorescence intensity of a single fluorophore that reacts with a specific radical can be affected 
by variations in radical and probe concentrations, instrumental artifacts and sensitivity to other 
environmental factors such as temperature and pH. In addition, real time in vivo imaging 
becomes challenging if the probe reacts with other molecules present in the cellular media,  
undergoes photobleaching or generates other secondary radicals.
11
 A novel approach for 
detection of hydroxyl radicals is the use of fluorescence ratiometric detection that likely reduces 
such limitations. In this case, the ratio between the fluorescence intensity of a reporting molecule 
and the fluorescence intensity of a reference molecule can be used. Such ratiometric fluorescent 
sensors were reported for the detection of hydrogen peroxide and hydroxyl radicals using 
coumarin-coupled dyes.
21, 22
 Another interesting approach is the use of ratiometric nanoparticles. 
For example, C3C-coupled polyacrylamide nanoparticles incorporating Texas Red as reference 
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dye were used as ratiometric nanoparticles, and hydroxyl radicals were detected based on the 
fluorescence intensity ratio between the two dyes.
23
 Although such ratiometric sensors were used 
for the detection of free radicals, their limited solubility in aqueous media required the use of 
organic solvents that can act as radical scavengers. In addition, the compatibility of nanoparticle 
sensors with biological samples should be addressed in case of in vitro detection of hydroxyl 
radicals. 
In this study, we adopted a strategy where biocompatible poly-lactide-co-glycolide 
(PLGA) nanoparticles were used as ratiometric fluorescent nanosensors for hydroxyl radical 
detection. The design of the ratiometric nanosensor is illustrated in Figure 4.1. Novel lysine-
based molecular micelles containing a C3C moiety as the hydrophilic head group were 
synthesized and used as emulsifiers in the synthesis of PLGA nanoparticles by emulsification 
solvent evaporation. Such micelles have a polymerized highly hydrophobic core that strongly 
interacts with polymeric nanoparticles while the hydrophilic head group remains at the interface 
with aqueous solutions. The coumarin moiety is covalently bound to the lysine-based hydrophilic 
group that is present exclusively on the surface of the nanosensors and in direct contact with 
hydroxyl radicals present in the investigated samples. In order to complete the ratiometric 
scheme, neutral red dye was encapsulated into the nanoparticle matrix, protected from potential 
side reactions with free radicals. Other nanoparticles containing only C3C moiety or only NeR 
dye were also synthesized using emulsification solvent evaporation, and used as controls in the 
detection of hydroxyl radicals. The fluorescence intensity ratio between coumarin and neutral red 
was dependent on reaction time, nanoparticle concentration, and hydroxyl radical concentration. 
In addition, the response of C3C-poly-Nε-SUK – modified NeR – loaded PLGA nanoparticles 
was investigated in the presence of other reactive oxygen species such as superoxide anion 
radical, hydrogen peroxide, hypochlorite and singlet oxygen. Furthermore, the ratiometric 
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nanoparticles were incubated with MCF-7 breast tumor cells that were exposed to H2O2 – 
induced oxidative stress, and the detection of hydroxyl radicals was observed using fluorescence 
microscopy. 
 
 
Figure 4.1 Design of the ratiometric nanosensor. 
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4.2 Experimental 
4.2.1 Materials 
Poly (D,L-lactide-co-glycolide) (PLGA, lactide:glycolide 50:50, MW 40,000-75,000), 
sodium dodecyl sulfate (SDS), undecylenic acid, ethyl acetate, trifluoroacetic acid (TFA), 
sodium carbonate, coumarin 3-carboxylic acid, Nε-Boc lysine, dimethyl sulfoxide (DMSO), 
anhydrous dimethyl formamide (DMF), sucrose, hydrogen peroxide, and neutral red (NeR) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). NeR was neutralized with NaOH in 
water, resulting into a red precipitate that was freeze-dried and used further in nanoparticle 
synthesis. Dibasic sodium phosphate was purchased from Mallinckrodt (Hazelwood, MO, USA). 
N-hydroxysuccinimide (NHS), N,N’-dicyclohexylcarbodiimide (DCC), and cuprous sulfate were 
purchased from Fluka (Milwaukee, WI, USA). Dichloromethane (DCM), sodium phosphate 
monobasic, isopropyl alcohol, tetrahydrofuran, and hexanes were purchased from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Sodium bicarbonate and sodium hydroxide were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Doubly-distilled deionized water was 
obtained from an ELGA PURELAB Ultra water polishing system (US Filter, Lowell, MA, 
USA). All reagents were of analytical grade and were used as received.  
4.2.2 Synthesis of Coumarin Functionalized Molecular Micelles 
The amino acid based molecular micelle poly (sodium N-undecenyl-Nε-Boc lysinate) 
(poly- Nε-Boc-SUK) was synthesized according to the procedure described by Macossay et al.
24
 
The deprotection of Boc group was achieved in a mixture of DCM and TFA 1:1 v/v for 4 hours 
at room temperature. The synthesis scheme of C3C-poly-Nε-SUK is presented in Figure 4.2. The 
first step is represented by the activation of carboxylic group of C3C, resulting in the 
succinimidyl ester of C3C (SECCA), according to an modified procedure described by Bardajee 
et al.
25
 The unprotected poly-Nε-SUK (100 mg) was dissolved in sodium carbonate 0.1 M (5mL) 
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followed by the addition of SECCA dissolved in 1:4 v/v DMSO:DMF (5 mL) and allowed to 
react overnight. The solvent was removed by dialysis (cellulose ester membrane, MWCO 1000 
Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA) for 24 hours. The final product, 
C3C-poly-Nε-SUK, was freeze-dried and refrigerated. Proton NMR indicated the completion of 
the coupling reaction by the presence of coumarin chemical shifts in the 7-9 ppm region.  
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Figure 4.2 Synthesis of C3C-poly-Nε-SUK micelle. 
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4.2.3 Nanoparticle Synthesis 
PLGA nanoparticles were synthesized by use of an emulsification solvent evaporation 
method. Briefly 0.5 mL of 1 mg/mL NeR in DCM was added to 0.5 mL DCM solution 
containing 50 mg of PLGA. In case of blank nanoparticles, the dye solution was replaced with 
DCM. An aqueous phase was prepared by dissolving C3C-poly-Nε-SUK in 5 mL water. For 
non-C3C-functionalized neutral red loaded nanoparticles, C3C-poly-Nε-SUK was replaced with 
a non-functionalized Boc-protected poly-Nε-Boc-SUK molecular micelle. The organic phase 
was added dropwise to the aqueous phase under stirring conditions using a homogenizer (model 
398, Biospec Products, Inc., Racine, WI, USA), at 15,000 rpm for 2 minutes, resulting in a single 
o/w emulsion. The emulsion droplets were further reduced by sonication using a probe 
ultrasound processor (model VC750, Sonics and Materials Inc., Newton, CT, USA), operating at 
an amplitude intensity of 35 %, for 10 minutes. The solvent was evaporated using a rotary 
evaporator (Büchi rotovapor R-200, Brinkmann Instruments, Inc., Westbury, NY, USA). The 
nanoparticles were centrifuged at 10,000 rpm for 30 minutes, followed by washing by 
centrifugation in the same conditions. The nanoparticle suspension was stored at 4 ºC until 
further use. 
4.2.4 Nanoparticle Characterization 
Average particle diameter (Zave) and size distribution indicated by the polydispersity 
index (PDI) were measured by use of dynamic light scattering (DLS) (Zetasizer NanoZS, 
Malvern Instrumets Ltd., Malvern, UK) and reported as intensity distribution. Nanoparticle 
surface charge indicated by zeta potential was measured by use of laser doppler anemometry 
(Zetasizer NanoZS, Malvern Instrumets Ltd., Malvern, UK) using a capillary cell. The reported 
values of particle size, PDI, and zeta potential represent the average of three different 
nanoparticle batches. Nanoparticle morphology were investigated using transmission electron 
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microscopy (TEM) (JEOL 100CX, JEOL USA Inc., Peabody, MA, USA) operating at 80kV. A 
drop of nanoparticle suspension was dried at room temperature on a carbon coated copper grid 
and negatively stained using a 2 % solution of uranyl acetate. 
4.2.5 Dye Content 
The dye content was determined in the supernatant resulted from the centrifugation steps 
using absorbance spectroscopy (UV-3101PC UV-Vis-near-IR scanning spectrometer, Shimadzu, 
Columbia, MD) using a reduced volume (1.4 mL) quartz cuvet. A calibration curve was 
constructed for C3C by representing the absorbance intensity at 290 nm as a function of C3C 
concentration (y = 0.0111x-0.0258, R
2
 = 0.9927). Similarly,  a calibration curve was constructed 
for NeR by representing the absorbance intensity at 530 nm as a function of NeR concentration 
(y = 1.1178x-0.0019, R
2
 = 0.9989). The NeR entrapment efficiency was calculated by difference 
between found amount in the supernatant and the theoretical amount added to the formulation. 
The C3C coverage was calculated based on the C3C content of poly-Nε-SUK attached on the 
surface of nanoparticles after purification. 
4.2.6 Hydroxyl Radical Generation 
Hydroxyl radicals were generated in phosphate buffer (pH=7.4) based on the reaction of 
cuprous sulfate and hydrogen peroxide in the presence of ascorbic acid, as described by 
equations 4.1 and 4.2. The reduction of Cu
2+
 takes place in the presence of ascorbic acid 
resulting into Cu
+
 that further reacts with hydrogen peroxide leading to the formation of 
hydroxyl radicals. The concentration of OH
•
 was varied by varying the concentration of cuprous 
sulfate added to the reaction. For various experiments, the reaction was stopped at various time 
intervals using DMSO as OH
•
 scavenger.  
 ++  → CuCu acidascorbic2                 4.1 
−•++
++→+ OHOHCuOHCu 222                4.2 
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4.2.7 Fluorescence Spectroscopy 
Steady-state fluorescence spectra were recorded using Fluorolog-3 spectrometer (model 
FL1073, Horiba Jobin Yvon, Edison, NJ) operated in the front face mode, at 25 ºC as provided 
by a temperature control chamber. The samples were prepared in phosphate buffer (pH 7.4), and 
a short path (0.4 cm
2
) cuvette was used. The excitation and emission slit widths were both set at 
5 nm, respectively. The samples were excited at 410 nm, and the emission was collected from 
420 to 700 nm. The blanks containing all reagents except nanoparticles were subtracted for each 
sample. All measurements were performed in triplicate. 
4.2.8 In vitro Detection of Hydroxyl Radicals 
 Human mammary MCF-7 tumor cells (HTB-22, American Tissue Culture Collection, 
ATCC, Manassas, VA) were grown to 90% confluence according to ATCC’s instructions and 
used for in vitro detection of OH
•
 radicals. Specifically, the cells were incubated with 
nanoparticle suspension (0.07 mg/ mL cell suspension) in a 6-well plate at 10,000 cells/ well. 
After two hours of incubation, the cells were washed with growth media to eliminate the excess 
of nanoparticles. The cells were then exposed to H2O2-induced oxidative stress (400 µM) for 40 
minutes, and washed with phosphate buffer. Fluorescence images were taken before and after 
exposure, using a Leica DM RXA2 upright microscope (Leica Microsystems Inc., Bannockburn, 
IL) equipped with GFP and TRITC filter cubes, and an immersion 40X objective. 
4.3 Results and Discussion 
4.3.1 Nanoparticle Characterization 
In this study, C3C-poly-Nε-SUK – modified NeR loaded PLGA nanoparticles were 
prepared by emulsification solvent evaporation using fluorescent molecular micelles as 
emulsifiers. Previously, PLGA nanoparticles were successfully synthesized in our laboratory 
using molecular micelles as emulsifiers, offering great advantages such as small size, 
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monodisperse suspension, and excellent stability.
26
 The C3C-poly-Nε-SUK – modified NeR 
loaded PLGA nanoparticles synthesized in this study had a size of 124 ± 0.7 nm. In addition, the 
nanoparticle suspension was monodisperse as expressed by a PDI value of 0.052 ± 0.012. The 
anionic molecular micelle present on the nanoparticle surface conferred a zeta potential of -52.77 
± 0.76 mV, indicating high stability of nanoparticles in solution. Individual nanoparticles having 
spherical shape were observed by TEM, their micrograph being illustrated in Figure 4.3.  
 
 
Figure 4.3 TEM micrograph of C3C-poly-Nε-SUK – modified PLGA nanoparticles. 
 
Commercially available NeR is delivered as a chloride that is highly water soluble. In 
order to encapsulate it into PLGA nanoparticles, neutralization with NaOH was performed, and it 
resulted into a red precipitate consisting of highly hydrophobic neutralized NeR. The 
hydrophobic NeR dye was thus encapsulated in PLGA nanoparticles by an emulsification solvent 
evaporation method using C3C-poly-Nε-SUK as an emulsifier. The content of NeR was 
determined by UV spectroscopy, based on a calibration curve as described above. Taking into 
consideration the initial NeR amount added to the formulation, it was found that the NeR content 
was 83.9 ± 0.8%. Similarly, the C3C content given by the presence of C3C-poly-Nε-SUK was 
determined by UV spectroscopy. The C3C content was found to be 48.4 ± 0.9%, representing the 
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fraction of C3C amount present in the initial C3C-poly-Nε-SUK micelle used as emulsifier in the 
nanoparticle synthesis. 
4.3.2 Nanoparticle Reaction with Hydroxyl Radicals 
Hydroxyl radicals were detected using ratiometric fluorescence spectroscopy. Compared 
with variations of a single signal, ratiometric detection involves changes in the ratio of two 
signals. The first signal is given by a reporting dye that reacts with the molecule of interest, 
while the second signal is given by a reference dye that corrects for instrumental artifacts. 
Nanoparticles that contain both reference and reporting dyes can be used in the ratiometric 
detection scheme. In case of C3C-poly-Nε-SUK – modified NeR – loaded PLGA nanoparticles, 
NeR was the reference dye, and was encapsulated into PLGA nanoparticles. In addition, the 
reporting dye was 7-OH C3C-poly-Nε-SUK that resulted from the reaction with OH
•
 radicals of  
C3C-poly-Nε-SUK molecular micelle present on the nanoparticle surface. The product of such 
reaction presented a fluorescent signal at 450 nm when excited at 410 nm. At the same time, the 
reference dye, NeR, offered a separate fluorescent signal as shown in Figure 4.4.  
In order to demonstrate that the two fluorescent peaks were generated by C3C and NeR 
respectively, blank nanoparticles were prepared without NeR. These nanoparticles contained 
C3C-poly-Nε-SUK molecular micelle on the surface. In addition, NeR-loaded nanoparticles 
were prepared using a non-functionalized Boc-protected poly-Nε-Boc-SUK molecular micelle as 
emulsifier. The fluorescence spectrum of C3C-poly-Nε-SUK – modified blank nanoparticles 
presented the peak at 450 nm as a result of the reaction of OH
•
 radicals with C3C, while the 
fluorescence peak at 540 nm is absent. In contrast, the spectrum of Boc-protected poly-Nε-Boc-
SUK – modified NeR – loaded nanoparticles contained exclusively the fluorescence of reference 
dye NeR. Therefore, it was confirmed that the two peaks at 450 nm and 535 nm were generated 
by the reference and the reporting dyes, respectively. 
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 Figure 4.4 Normalized fluorescence of nanoparticles after the reaction with OH
•
 (0.07 
mg/mL nanoparticles, 200 µM CuSO4, 20 mM H2O2 and 200 µM ascorbic acid; 5 
minutes; total volume was 500 mL). 
 
 
4.3.2.1 Effect of Coumarin Location 
The reaction between OH
•
 radicals and C3C likely depends on the availability of the 
reagents. In the case of C3C-poly-Nε-SUK – modified NeR – loaded PLGA nanoparticles, C3C 
was placed near the surface of the nanoparticle, directly exposed to the environment containing 
OH
•
 radicals and readily available for the reaction. The effect of C3C location on the 
fluorescence response was observed by changing the position of C3C within the ratiometric 
nanosesor. Nanoparticles containing both C3C and NeR in the polymeric matrix were 
synthesized using non-fluorescent poly-Nε-Boc-SUK as emulsifier (poly-Nε-Boc-SUK – 
modified NeRSec – loaded PLGA nanoparticles). However, the succinimidyl ester of C3C 
(SECCA) was used instead of C3C, due to its higher hydrophobicity. It should be mentioned that 
SECCA readily reacts with OH
•
 radicals resulting in a fluorescent product having the intensity 
maximum at 450 nm.
15, 18
  The fluorescence spectra of C3C-poly-Nε-SUK – modified NeR – 
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loaded PLGA nanoparticles (red spectrum) and poly-Nε-Boc-SUK – modified NeRSec – loaded 
PLGA nanoparticles (blue and green spectra) are shown in Figure 4.5. The nanoparticles 
containing an equal molar ratio of SECCA and NeR within the polymer matrix presented a peak 
in the fluorescence spectrum at 538 nm likely due to NeR fluorescence, and no evident intensity 
of 7-OH C3C at 450 nm, as it can be noted in Figure 4.5 (blue spectrum).  
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Figure 4.5 Effect of C3C location. Corrected fluorescence of nanoparticles after the reaction 
with OH
•
 (0.07 mg/mL nanoparticles, 200 µM CuSO4, 20 mM H2O2 and 200 µM 
ascorbic acid; 5 minutes; total volume was 500 mL). 
 
 
As the amount of SECCA added to the nanoparticles increased to a 1:5 molar ratio, a 
portion of the dye was likely situated near the nanoparticle surface. Therefore, the reaction 
between SECCA and OH
•
 radicals readily occurred, and the peak at 450 nm appeared in the 
fluorescence spectrum. However, the overall fluorescence signal was lower for poly-Nε-Boc-
SUK – modified NeRSec – loaded PLGA nanoparticles than for C3C-poly-Nε-SUK – modified 
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NeR – loaded PLGA nanoparticles. Such results suggested that the presence of coumarin moiety 
on the surface of the nanoparticles generated the highest signal, likely due to availability of C3C 
for the reaction with OH
•
 radicals. 
4.3.2.2 Effect of Reaction Time 
 In general, hydroxyl radicals have a short life-time in solution and rapidly react with 
surrounding molecules. Due to sample preparation and instrumental limitation, the time needed 
for nanoparticle reaction with OH
•
 radicals was established by stopping the reaction at various 
time intervals using DMSO as OH
•
 scavenger. DMSO rapidly reacts with hydroxyl radicals and 
likely eliminates their presence in solution. In Figure 4.6, the I450/I528 ratio between C3C 
fluorescence intensity at 450 nm and NeR fluorescence intensity at 528 nm is represented as a 
function of time.  
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Figure 4.6 Effect of reaction time on fluorescence ratio after the reaction of nanoparticles 
with OH
•
 (0.07 mg/mL nanoparticles, 200 µM CuSO4, 20 mM H2O2 and 200 µM 
ascorbic acid; total volume 500 mL). 
 
A linear increase of I450/I528 is observed in the first minute, indicating that the radicals 
were rapidly consumed in the reaction with C3C. It is worth mentioning that the reaction of OH
•
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with C3C is irreversible, and limited by the concentration of radicals. After one minute, it is 
possible that OH
•
 radical concentration decreased. Therefore, further increase in the fluorescent 
ratiometric signal was not observed with increase in the reaction time. For further experiments, 
the reaction was stopped at 5 minutes in order to ensure the complete reaction. 
4.3.2.3 Effect of Nanoparticle Concentration 
Spectroscopic analyses using nanoparticle reactions with various molecules are limited 
by their scattering effect. Therefore, a minimum nanoparticle concentration is desirable that 
would be sufficient for the reaction and at the same time remains within the instrumental 
limitations. Figure 4.7 represents the fluorescence spectra of increasing concentrations of 
nanoparticle suspensions reacting with OH
•
 radicals. All other conditions were kept constant. It 
can be noted that the intensity of NeR at 528 nm increased with the increase in nanoparticle 
concentration. 
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Figure 4.7 Fluorescence spectra of nanoparticles after the reaction with OH
•
 (0.03, 0.07, 
0.10, 0.14, 0.21 mg/mL nanoparticles, 400 µM CuSO4, 20 mM H2O2 and 200 µM 
ascorbic acid, incubated for 5 min; total volume 500 mL). 
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However, as more nanoparticles were used in the reaction, the peak corresponding to 7-
OH C3C started to disappear under the NeR peak. Since the concentration of OH
•
 radicals 
remained constant, an increase in nanoparticle concentration did not produce an increase of 7-
OH peak, but resulted in an increase of only NeR peak. In addition, a significant cloudiness of 
reaction medium was observed at concentrations above 0.1 mg/mL nanoparticle solution. A 
minimum concentration of 0.07 mg/mL nanoparticles was considered optimum for ratiometric 
experiments, firstly to produce a clear response at 450 and 528 nm, and secondly to minimize the 
scattering effect.  
4.3.2.4 Effect of Hydroxyl Radical Concentration 
 Increasing concentrations of OH
•
 radicals were incubated with C3C-poly-Nε-SUK – 
modified NeR – loaded PLGA nanoparticles. In case of ratiometric sensors, if the reporting and 
reference dyes are in close proximity, and there is an overlap between the fluorescence of the 
reporting dye and the absorbance of the reference dye, fluorescence resonance energy transfer 
(FRET) occurs.  In this case, the signal of the reporting dye decreases and the one of the 
reference dye increases. The reporting dye signal strictly depends on the reaction with OH
•
 
radicals, and an increase in radical concentration would likely produce an increase in the 
reporting dye signal. The response of C3C-poly-Nε-SUK – modified NeR – loaded PLGA 
nanoparticles to different concentrations of OH
•
 radicals is illustrated in Figure 4.8(A).  
In this experiment, the concentration of OH
•
 was changed by changing the concentration 
of CuSO4, according to equations 4.1 and 4.2. The other conditions were maintained constant. As 
the OH
•
 concentration increases, it is expected that C3C present on the surface of nanoparticles 
to generate an increase in the fluorescence intensity at 450 nm. However, an increase in NeR 
signal was observed while the signal from 7-OH C3C decreased due to a fluorescence energy 
transfer between the coumarin and the reference dye.  
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Figure 4.8 (A) Fluorescence spectra of nanoparticles after the reaction with OH
•
 (0.07mg/mL 
nanoparticles, 20 mM H2O2, 200 µM ascorbic acid, and 10, 20, 30, 40, 50, 100, 
200, 400, and 1000 µM CuSO4, incubated for 5 min; total volume 500 mL); (B) 
logarithmic I450/I528 ratio as a function of CuSO4 concentration. 
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In addition, the observed FRET phenomenon was favored by the spectral overlap and 
short spatial distance between the reporting and reference dyes. The I450/I528 ratio between C3C 
fluorescence intensity at 450 nm and NeR fluorescence intensity at 528 nm is represented as a 
function of CuSO4 concentration in Figure 4.8(B) on a logarithmic scale. It can be observed that 
the fluorescence intensity ratio increases as the concentration OH
•
 radicals increases. In order to 
verify that the increase in the NeR signal was determined by FRET, NeR – loaded PLGA 
nanoparticles modified with poly-N-Boc-SUK micelles were also incubated with increasing 
concentrations of hydroxyl radicals, and compared with C3C-poly-Nε-SUK – modified NeR – 
loaded PLGA nanoparticles. We noticed an insignificant increase in the NeR peak as compared 
with the increase determined by the presence of C3C (as shown in Appendix IV.A). 
4.3.3 Reaction with Other Radicals 
The selectivity of nanoparticles for OH
•
 radicals is important in particular for radical 
detection in biological samples. NeR-loaded PLGA nanoparticles modified with C3C-poly-Nε-
SUK were exposed to various radical and non-radical reactive species such as superoxide anion
 
(O2
•-
), hydrogen peroxide (H2O2), singlet oxygen
 
(
1
O2), and hypochlorite anion (OCl
-
). The 
reactions took place in phosphate buffer using the same nanoparticle concentration, reaction 
volume and reaction time. DMSO was used only for the detection of hydroxyl radicals. The ratio 
between C3C fluorescence intensity at 450 nm and NeR fluorescence intensity  at 528 nm 
(I450/I528) is represented in Figure 4.9 for each radical. It can be noted that the I450/I528 ratio was 
significantly higher for OH
•
 than for the other radicals, indicating increased nanosensor 
selectivity towards hydroxyl radical likely determined by the selectivity of C3C. 
4.3.4 In vitro Detection of Hydroxyl Radicals 
Aerobic organisms are complicated machines that produce energy based on oxidation 
reactions. Such reactions generate reactive oxygen species that are involved in diseases such as 
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cancer, diabetes and ageing. In comparison with other reactive oxygen species, hydroxyl radical 
is a short life radical. In addition, it can react with numerous biological molecules including 
lipids, proteins and DNA. In order to verify the ability of C3C-poly-Nε-SUK – modified NeR – 
loaded PLGA nanoparticles to react with OH
•
 radicals generated in cell cultures, MCF-7 breast 
tumor cells were incubated with ratiometric nanoparticles for 2 hours. 
 
 
 
Figure 4.9 Fluorescence spectra of nanoparticles after the reaction with various radicals (0.07 
mg/mL nanoparticles, and OH
•
 (400 µM CuSO4, 20 mM H2O2 and 200 µM 
ascorbic acid), O2
-•
 (200 µM KO2), H2O2 (20 mM), OCl
-
 (200 µM NaOCl), 
1
O2 
(200 µM H2O2 + 200 µM NaOCl). 
 
 
After the nanoparticle cell uptake took place, the cells were washed in order to eliminate 
the excess of nanoparticles. The cells were further exposed to oxidative stress using hydrogen 
peroxide as initiator. In the cellular environment, hydroxyl radicals are mainly generated by the 
reaction of hydrogen peroxide with metals, and likely contained the transition metals necessary 
for the reaction with hydrogen peroxide. The fluorescent signal was observed by fluorescence 
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microscopy at different incubation times as shown in Figure 4.10. Initially the cells appeared red 
likely due to the NeR signal. As the OH
•
 radicals became available in the cell environment at 10, 
20 and 40 minutes, the cells started to turn green possibly as a result of 7-OH C3C fluorescence 
signal. Therefore, ratiometric C3C-poly-Nε-SUK – modified NeR – loaded PLGA nanoparticles 
were able to detect free radicals in stressed cells. It should be mentioned that C3C can react with 
OH
•
 radicals that are also produced through natural metabolism of viable cells. However, their 
presence did not generate green fluorescence during the nanoparticle cellular uptake. In oxidative 
stress conditions, the concentration of OH
•
 radicals is higher as compared with normal 
conditions, allowing their rapid detection in viable cells using ratiometric nanoparticles. 
The MCF-7 cells were also incubated with NeR-loaded nanoparticles modified with a 
non-fluorescent Boc-protected poly-SUK. In this experiment, the cells appeared red before the 
exposure to oxidative stress, and remained mainly red after the exposure to oxidative stress, the 
weak green color being observed likely due to cell autofluorescence. Similarly, the cells were 
incubated with C3C-poly-Nε-SUK – modified blank PLGA nanoparticles. No fluorescence was 
observed before the exposure to oxidative stress. However, the cells became green after the 
exposure to oxidative stress, likely due to coumarin reaction with hydroxyl radicals (as shown in 
Appendix IV.B). 
4.4 Conclusions 
Detection of reactive oxygen species is critical for the investigation of their role in 
biological systems, and a suitable analytical method is desirable for their rapid detection. 
Hydroxyl radical is one of the most important radical involved in oxidative stress, mainly due to 
its high reactivity. In this study, C3C-poly-Nε-SUK – modified NeR – loaded PLGA 
nanoparticles were used to successfully detect hydroxyl radicals by fluorescence ratiometric 
detection conferred by 7-OH C3C reporting dye and NeR reference dye. In addition, the 
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ratiometric nanoparticles were sensitive and selective for hydroxyl radicals as compared to other 
reactive oxygen species such as superoxide anion
 
(O2
•-
), hydrogen peroxide (H2O2), singlet 
oxygen
 
(
1
O2), and hypochlorite (OCl
-
). Furthermore, C3C-poly-Nε-SUK – modified NeR – 
loaded PLGA nanoparticles were able to detect hydroxyl radicals in viable cells exposed to 
oxidative stress allowing their potential use in the study of other living systems. 
 
 
 
Figure 4.10 Fluorescence micrographs of nanoparticle response in MCF-7 cells exposed to 
H2O2 – induced oxidative stress (400 µM), before the addition of H2O2 (top left 
corner), at t = 10, 20, and 40 minutes after the addition of H2O2. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE STUDIES 
 
The major goal of this dissertation was to demonstrate the utility of molecular micelles in 
nanoparticle synthesis. Molecular micelle – modified polymeric nanoparticles can be used as 
drug delivery systems for delivery of antioxidants. In addition, they can serve as nanoparticle – 
based analytical sensors for detection of free radicals. The importance of drug delivery systems 
and the use of polymeric nanoparticles as drug delivery systems were emphasized in the first 
chapter of this dissertation. In addition, methods of nanoparticle synthesis and nanoparticle 
characterization were described in detail. Molecular micelles were compared with conventional 
micelles, and their utility in nanoparticle synthesis was revealed. The concepts of antioxidants, 
oxidative stress and free radicals were introduced as well. Chemometrics and optimization 
designs played an important role in the research included in this dissertation and were described 
in the first chapter as well. 
In the second chapter, molecular micelles were used as novel emulsifiers in the synthesis 
of poly (D,L lactide-co-glycolide) (PLGA) nanoparticles by emulsification solvent evaporation. 
Examples of such micelles include poly (sodium N-undecenyl sulfate) (poly-SUS), poly (sodium 
N-undecenyl-glycinate) (poly-SUG) and poly (sodium N-undecenyl-L-leucyl-valinate) (poly-L-
SULV). Other emulsifiers, such as anionic sodium dodecyl sulfate (SDS) and non-ionic poly 
(vinyl alcohol) (PVA) were used for comparison. The optimization of nanoparticle synthesis was 
achieved by the use of a central composite experimental design (CCD). The individual and 
combined effects of PLGA concentration, emulsifier concentration, homogenization speed, and 
sonication time (design variables) on particle size and polydispersity index (responses) were 
investigated using multivariate analysis. The most significant design variables influencing the 
nanoparticle size and size distribution were PLGA concentration and emulsifier concentration (p 
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< 0.05) in comparison to the other design variables. The quadratic model demonstrated the 
highest predictive ability when the molecular micelles were used as emulsifiers. The PLGA 
nanoparticles optimally synthesized according to the CCD were further purified by dialysis and 
then freeze-dried. Dried nanoparticles synthesized with molecular micelles and PVA were 
readily re-suspended in water, as compared with SDS for which nanoparticle aggregation 
occurred. The size of PLGA nanoparticles synthesized using molecular micelles increased after 
freeze-drying, but remained below 100 nm when poly-L-SULV was used as emulsifier. The PDI 
values indicated monodisperse nanoparticle suspensions after purification and freeze-drying for 
all investigated molecular micelles (PDI < 0.100). The nanoparticle suspensions synthesized 
using molecular micelles were the most stable after dialysis and freeze-drying, having low 
negative zeta potential values ranging from - 54 ± 1.6 mV for poly-L-SULV to - 63.2 ± 0.4 mV 
for poly-SUS. Transmission electron microscopy (TEM) micrographs showed spherical shapes 
and smooth surfaces for the molecular micelle – modified PLGA nanoparticles.  
In the third chapter of this dissertation, anionic amino acid - based molecular micelles 
were used as emulsifiers in the synthesis of thymoquinone (TQ)-loaded PLGA nanoparticles by 
use of an emulsification solvent evaporation method.  The nanoparticle synthesis was optimized 
for maximum entrapment efficiency using a Box-Behnken experimental design.  Optimum 
conditions were found to be 100 mg PLGA, 15 mg TQ and 0.5% w/v emulsifier [poly(sodium N-
undecenyl-glycinate) (poly-SUG)].  In addition, other structurally related molecular micelles 
having various amino acid head groups and different hydrophobic carbon chain lengths were also 
examined as emulsifiers, and provided excellent emulsifier properties, leading to monodispersed 
particle sizes below 200 nm, and maximum entrapment efficiency.  In vitro release studies 
revealed a rapid TQ release in the first 8 hours, the highest release levels being obtained for poly-
SUG and poly(sodium N-heptenyl-glycinate) (poly-SHG).  The antioxidant activity of TQ-
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loaded nanoparticles, indicated by IC50 (mg/mL TQ for 50% 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) scavenging activity), was the highest for poly(sodium N-undecenyl-alaninate) (poly-
SUA)-emulsified nanoparticles (0.023±0.001 mg/mL), representing an improvement factor of 
5.7 as compared to free TQ.  In addition, TQ-loaded nanoparticles showed lower cytotoxic 
effects than the equivalent free TQ for normal (Hs578Bct) breast cells, indicating a protective 
effect provided by the nanoparticles.  For MCF-7 breast cancer cells, the lowest cell viability was 
obtained for poly(sodium N-undecenyl-leucinate) (poly-SUL) – emulsified nanoparticles 
(43.26±9.45%), which is comparable to free TQ (37.42±4.83%).  In addition, TQ-loaded 
nanoparticles emulsified with poly(sodium N-undecenyl-valinate) (poly-SUV) were more 
effective for MDA-MB-231 breast cancer cell inhibition (68.47±8.42%) than free TQ. Molecular 
micelles offered high flexibility to nanoparticle physico-chemical and biological properties and, 
therefore, can be used in the synthesis of drug-loaded nanoparticles depending on the desired 
properties.  In addition, such nanoparticles are promising as free radical scavengers and 
inhibitors of breast cancer cells. 
Molecular micelle – modified nanoparticles are not only an example of drug delivery 
systems, but nanosensors that can be used for detection of various molecules. In the fourth 
chapter of this dissertation, polymeric nanoparticles were synthesized using fluorescent labeled 
molecular micelles that served as detectors for hydroxyl radicals. Specifically, poly (sodium N-
undecenyl - Nε - lysinate) (poly-Nε-SUK) functionalized with coumarin 3-carboxylic acid (C3C) 
was used as emulsifier in the synthesis of neutral red (NeR) - loaded PLGA nanoparticles by 
emulsification – solvent evaporation. Ratiometric fluorescence spectroscopy was applied for the 
detection of hydroxyl radicals based on the intensity ratios of a reporting and reference dyes, 
respectively. The product of C3C reaction with hydroxyl radical, 7-hydroxy coumarin 3-
carboxylic acid (7-OH C3C) represented the reporting dye, while NeR encapsulated into the 
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nanoparticles was the reference dye. Other fluorescent and non-fluorescent molecular micelles 
were used in the synthesis of control nanoparticles. C3C-poly-Nε-SUK – modified NeR-loaded 
nanoparticles were able to detect hydroxyl radicals in simulated samples as well as biological 
samples exposed to oxidative stress. Furthermore, the ratiometric nanoparticles were selective 
for hydroxyl radicals as compared to other reactive oxygen species including superoxide anion
 
(O2
•-
), hydrogen peroxide (H2O2), singlet oxygen
 
(
1
O2), and hypochlorite (OCl
-
).  In addition to 
nanosensor spectral properties, their low toxicity and fast cellular uptake allow their potential use 
in the study of other living systems. 
The research presented in this dissertation demonstrated the utility of molecular micelles 
in nanoparticle synthesis, their versatility that conferred tunable properties for drug loaded 
nanoparticles, and their ability to offer functional groups for analytical purposes. Molecular 
micelle – modified nanoparticles are not only an example of drug delivery systems, but 
nanosensors that can be used for detection of various molecules. Their biodegradability and 
biocompatibility represent great advantages as compared with toxicity of other nanoparticles 
used for analytical purposes.  
There are multiple possibilities for further use of molecular micelle – modified  
nanoparticles. Taking into consideration the fact that many antioxidants exhibit protective effects 
in chemotherapy and some of them have anticancer properties, the co-entrapment of multiple 
antioxidants and anticancer drugs having both scavenging and anticancer properties can be 
studied as potential treatment for various cancers. In addition, there is a large variety of 
molecules that can be covalently attached to molecular micelles. Several examples include 
fluorescent dyes, near infrared dyes, folate-based conjugates, aptamers, and others. Such 
molecules can serve multiple purposes ranging from targeted delivery to detection of small 
reactants and disease biomarkers in biological systems.  
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APPENDIX I 
GENERAL SYNTHESIS SCHEME OF MOLECULAR MICELLES 
 
 
 
Appendix I.A  Synthesis of Poly-SUS. 
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Appendix I.B  Synthesis of amino acid and dipeptide based molecular micelles. 
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APPENDIX II 
EXPERIMENTAL CONDITIONS USED IN THE CENTRAL COMPOSITE DESIGN 
 
Experimental conditions 
Exp. 
No. 
PLGA  
(% (w/v)) 
Emulsifier 
(% (w/v)) 
H. speed 
(rpm) 
S. time 
(min) 
1 5.0 1.00 10,000 5 
2 3.5 0.55 15,000 10 
3 5.0 1.00 20,000 15 
4 5.0 1.00 10,000 15 
5 0.5 0.55 15,000 10 
6 2.0 1.00 20,000 15 
7 2.0 0.10 10,000 15 
8 5.0 1.00 20,000 5 
9 2.0 0.10 10,000 5 
10 3.5 0.55 25,000 10 
11 6.5 0.55 15,000 10 
12 2.0 0.10 20,000 5 
13 2.0 1.00 10,000 5 
14 3.5 0.05 15,000 10 
15 3.5 0.55 15,000 20 
16 3.5 0.55 15,000 10 
17 3.5 0.55 5,000 10 
18 3.5 0.55 5,000 0 
19 3.5 1.45 15,000 10 
20 3.5 0.55 15,000 10 
21 2.0 1.00 10,000 15 
22 5.0 0.10 20,000 15 
23 3.5 0.55 15,000 10 
24 2.0 0.10 20,000 15 
25 5.0 0.10 20,000 5 
26 2.0 1.00 20,000 5 
27 3.5 0.55 15,000 10 
28 5.0 0.10 10,000 5 
29 5.0 0.10 10,000 15 
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APPENDIX III 
RESULTS OF ANALYSIS OF VARIANCE FOR CENTRAL COMPOSITE DESIGN 
 
Particle size (Zave) 
 SDS PVA Poly-SUS Poly-SUG Poly-L-SULV 
R
2 
0.953 0.933 0.937 0.966 0.985 
 p bxy p bxy p bxy p bxy p bxy 
b0 0.00 55.77 0.00 312.74 0.00 126.14 0.00 134.69 0.00 139.01 
X1 0.00 4.38 0.00 21.95 0.00 8.77 0.00 5.47 0.00 9.94 
X2 0.00 -26.82 0.00 -266.23 0.00 -52.20 0.00 -76.95 0.00 -49.84 
X3 0.46 0.00 0.45 0.00 0.83 0.00 0.25 0.00 0.12 0.00 
X4 0.13 -0.33 0.02 -5.90 0.01 -1.35 0.00 -1.54 0.00 -1.99 
X1X2 0.00 -4.21 0.02 -26.11 0.44 -1.60 0.51 1.34 0.59 -0.54 
X1X3 0.50 0.69 0.46 -7.93 0.70 0.85 0.32 2.24 0.15 -1.76 
X1X4 0.89 -0.13 0.34 -9.40 0.29 2.16 0.05 4.32 0.00 4.01 
X2X3 0.27 1.07 0.29 10.83 0.49 -1.43 0.79 -0.53 0.00 3.77 
X2X4 0.11 1.44 0.18 12.60 0.26 2.15 0.03 4.55 0.00 -4.40 
X3X4 0.15 -1.35 0.18 13.27 0.32 1.99 0.18 2.79 0.06 2.23 
X1
2 
0.16 1.16 0.73 2.87 0.49 -1.19 0.63 0.86 0.01 -2.80 
X2
2 
0.00 6.13 0.00 44.11 0.00 9.70 0.00 10.72 0.00 10.75 
X3
2 
0.86 -0.14 0.43 6.62 0.80 0.44 0.09 3.21 0.37 0.79 
X4
2 
0.06 1.74 0.04 19.79 0.12 2.98 0.03 4.68 0.45 0.78 
 
Appendix III.A Analysis of variance for particle size. 
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Polydispersity Index (PDI) 
 SDS PVA Poly-SUS Poly-SUG Poly-L-SULV 
R
2 0.872 0.970 0.773 0.743 0.914 
 p bxy p bxy p bxy p bxy p bxy 
b0 0.00 0.00 0.13 0.00 0.14 0.00 0.09 0.00 0.11 0.00 
X1 0.00 0.00 -0.01 0.01 0.01 0.41 0.00 0.31 0.00 0.05 
X2 0.00 0.00 0.04 0.00 -0.22 0.00 0.06 0.00 0.04 0.00 
X3 0.46 0.02 0.00 0.34 0.00 0.53 0.00 0.37 0.00 0.68 
X4 0.13 0.74 0.00 0.53 0.00 0.95 0.00 0.52 0.00 0.66 
X1X2 0.00 0.00 -0.02 0.00 -0.02 0.40 0.00 0.14 -0.01 0.06 
X1X3 0.50 0.04 -0.01 0.94 0.00 0.30 0.00 0.36 0.00 0.66 
X1X4 0.89 0.48 0.00 0.92 0.00 0.90 0.00 0.46 0.00 0.61 
X2X3 0.27 0.67 0.00 0.34 0.01 0.80 0.00 0.51 0.00 0.53 
X2X4 0.11 1.00 0.00 0.30 0.01 0.51 0.00 0.23 0.01 0.19 
X3X4 0.15 0.41 0.00 0.23 0.01 0.21 -0.01 0.77 0.00 0.91 
X1
2 
0.16 0.04 0.01 0.84 0.00 0.73 0.00 0.27 0.00 0.02 
X2
2 
0.00 0.69 0.00 0.00 0.04 0.05 -0.01 0.12 -0.01 0.00 
X3
2 
0.86 0.11 0.01 0.45 0.00 0.73 0.00 0.92 0.00 0.93 
X4
2 
0.06 0.49 0.00 0.00 0.03 0.22 0.00 0.10 -0.01 0.23 
 
Appendix III.B Analysis of variance for polydispersity index. 
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APPENDIX IV 
FLUORESCENCE OF NEUTRAL RED LOADED PLGA NANOPARTICLES 
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Appendix IV.A Fluorescence spectra of nanoparticles after the reaction with OH
•
 (0.07 
mg/mL nanoparticles, 20 mM H2O2, 200 µM ascorbic acid, 20 and 40 µM 
CuSO4, incubated for 5 min; total volume 500 mL) 
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 C3C-poly-Nε-SUK – modified NeR-loaded PLGA nanoparticles 
 
 
C3C-poly-Nε-SUK – modified blank PLGA nanoparticles 
 
Appendix IV.B Fluorescence micrographs of nanoparticle response in MCF-7 cells before 
and after exposure to H2O2 – induced oxidative stress (400 µM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before reaction with OH•  After reaction with OH•  
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